EP2205357B1 - Assay device and method - Google Patents
Assay device and method Download PDFInfo
- Publication number
- EP2205357B1 EP2205357B1 EP07823995.1A EP07823995A EP2205357B1 EP 2205357 B1 EP2205357 B1 EP 2205357B1 EP 07823995 A EP07823995 A EP 07823995A EP 2205357 B1 EP2205357 B1 EP 2205357B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- liquid
- channel
- reagent
- junction
- channel portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000003556 assay Methods 0.000 title claims description 151
- 238000000034 method Methods 0.000 title description 56
- 239000007788 liquid Substances 0.000 claims description 386
- 239000003153 chemical reaction reagent Substances 0.000 claims description 240
- 239000002245 particle Substances 0.000 claims description 118
- 239000000758 substrate Substances 0.000 claims description 112
- 238000001514 detection method Methods 0.000 claims description 71
- 230000000694 effects Effects 0.000 claims description 50
- 239000012530 fluid Substances 0.000 claims description 33
- 230000002209 hydrophobic effect Effects 0.000 claims description 14
- 238000012546 transfer Methods 0.000 claims description 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 239000000523 sample Substances 0.000 description 219
- 239000012491 analyte Substances 0.000 description 138
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 58
- 101800001904 NT-proBNP Proteins 0.000 description 54
- 102400001263 NT-proBNP Human genes 0.000 description 54
- 210000004369 blood Anatomy 0.000 description 48
- 239000008280 blood Substances 0.000 description 48
- 239000011230 binding agent Substances 0.000 description 46
- 239000000872 buffer Substances 0.000 description 43
- 239000007789 gas Substances 0.000 description 41
- 229940088598 enzyme Drugs 0.000 description 36
- 102000004190 Enzymes Human genes 0.000 description 31
- 108090000790 Enzymes Proteins 0.000 description 31
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 31
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical group [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 28
- 238000003745 diagnosis Methods 0.000 description 23
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 22
- 230000007306 turnover Effects 0.000 description 22
- 238000005259 measurement Methods 0.000 description 21
- 206010019280 Heart failures Diseases 0.000 description 18
- 230000033001 locomotion Effects 0.000 description 17
- 238000009739 binding Methods 0.000 description 16
- 230000008859 change Effects 0.000 description 16
- 230000027455 binding Effects 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 11
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 11
- 229960002685 biotin Drugs 0.000 description 11
- 235000020958 biotin Nutrition 0.000 description 11
- 239000011616 biotin Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 10
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 10
- 108010090804 Streptavidin Proteins 0.000 description 10
- 239000000090 biomarker Substances 0.000 description 10
- 230000009969 flowable effect Effects 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 230000003287 optical effect Effects 0.000 description 10
- 239000007853 buffer solution Substances 0.000 description 9
- 230000009471 action Effects 0.000 description 8
- 239000006249 magnetic particle Substances 0.000 description 8
- 230000001575 pathological effect Effects 0.000 description 8
- 230000003068 static effect Effects 0.000 description 8
- 230000005499 meniscus Effects 0.000 description 7
- 238000004393 prognosis Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000008279 sol Substances 0.000 description 7
- 239000000337 buffer salt Substances 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000004448 titration Methods 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 238000002848 electrochemical method Methods 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 230000004962 physiological condition Effects 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 239000001103 potassium chloride Substances 0.000 description 5
- 235000011164 potassium chloride Nutrition 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000001632 sodium acetate Substances 0.000 description 5
- 235000017281 sodium acetate Nutrition 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 206010007558 Cardiac failure chronic Diseases 0.000 description 4
- 229910021607 Silver chloride Inorganic materials 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000000835 electrochemical detection Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- -1 pentane sulfides Chemical class 0.000 description 3
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 240000003291 Armoracia rusticana Species 0.000 description 2
- 235000011330 Armoracia rusticana Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 150000003841 chloride salts Chemical class 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000007812 electrochemical assay Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000003905 indoor air pollution Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000276 potassium ferrocyanide Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 101500026734 Homo sapiens NT-proBNP Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 206010055670 Necrotising ulcerative gingivostomatitis Diseases 0.000 description 1
- 208000006595 Necrotizing Ulcerative Gingivitis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical group S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 1
- 208000019269 advanced heart failure Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000011365 complex material Substances 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940117389 dichlorobenzene Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000000840 electrochemical analysis Methods 0.000 description 1
- 230000005518 electrochemistry Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 108010023015 ischemia-modified albumin Proteins 0.000 description 1
- 230000002361 ketogenic effect Effects 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 239000002082 metal nanoparticle Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024535 susceptibility to myocardial infarction Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000019270 symptomatic heart failure Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 1
- 229910001887 tin oxide Inorganic materials 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502761—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/14—Process control and prevention of errors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/14—Process control and prevention of errors
- B01L2200/148—Specific details about calibrations
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
- B01L2300/0645—Electrodes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0864—Configuration of multiple channels and/or chambers in a single devices comprising only one inlet and multiple receiving wells, e.g. for separation, splitting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0887—Laminated structure
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/043—Moving fluids with specific forces or mechanical means specific forces magnetic forces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/06—Valves, specific forms thereof
- B01L2400/0688—Valves, specific forms thereof surface tension valves, capillary stop, capillary break
Definitions
- the present invention relates to assays.
- Heart failure is a chronic, progressive disease that affects a substantial portion of the world's population.
- the prevalence and incidence of heart failure is growing due to an aging population and a greater number patients who survive a myocardial infarction.
- heart failure can be characterized by a syndrome of breathlessness and fatigue, often accompanied by fluid retention, as indicated by an elevated jugular venous pressure and edema.
- the progression of heart failure is defined in four stages.
- the term heart failure refers to all of these.
- Stage A-at risk patients at high-risk of developing heart failure (patients with coronary heart disease, diabetes, hypertension, and/or valvular heart disease).
- Stage B-pre-heart failure patients with structural heart disease but without clinical heart failure symptoms, many of whom have decreased systolic function.
- Stage C-heart failure patients who have prior or current symptomatic heart failure due to systolic or diastolic dysfunction and who are responding to therapy.
- Stage D-advanced heart failure patients in end-stage or refractory-to-therapy.
- WO 2007/002579 relates to devices and methods for performing a test to detect and/or quentify the presence of an analyte of interest within a sample using a portable instrument.
- US 5,279,936 relates to methods for separating a component of interest from a mixture containing the component of interest and other components.
- WO 2007/110779 relates to an essay method and device that can perform at least one assay on a single aliquot of a sample liquid.
- the device can mix the sample liquid with assay reagents including magnetically susceptible particles.
- WO 2007/110739 relates to a method and apparatus for processing of particles in which the particles suspended in a first fluid are introduced under laminar flow conditions into at least one first micro chamber of first region of the same, in which a second fluid is introduced under laminar flow conditions into at least one second region of the micro chamber or a second micro chamber in such a way as not to mix with the first fluid.
- the present invention relates to assays.
- Also disclosed is a method comprising: (a) introducing a liquid sample to a first portion of a channel of a micro fluidic device; (b) contacting, within the microfluidic device, reagent with the liquid sample; (c) contacting, within the microfluidic device, liquid sample with a second liquid wherein the second liquid contains substrate of the reagent; (d) detecting a characteristic of the substrate in the second liquid at a first position in the microfluidic device; (e) contacting the second liquid with reagent at a second position in the microfluidic device and detecting a characteristic of the contacted substrate and/or reagent; (f) contacting reagent from said liquid sample with substrate in the second liquid and detecting a characteristic of the contacted liquid sample reagent and/or substrate; (g) using the characteristics detected in (d) and (e) to validate or adjust the characteristic detected in (f).
- detection of a characteristic of the substrate at the first position is in the absence of reagent, i.e. reagent concentration is zero.
- the second liquid has not contacted reagent.
- step (d) can comprise contacting the second liquid with a first concentration of reagent and detecting a characteristic of the contacted substrate and/or reagent at the first position.
- substrate in the second liquid can contact a second concentration of reagent wherein the second concentration of reagent is different to the first concentration of reagent.
- contacting of the liquid sample with second liquid comprises forming, proximal to a junction between the first portion of the channel and a second portion of the channel, a liquid sample:gas interface; and forming a liquid sample:second liquid interface by flowing a second liquid toward said junction and displacing gas of the liquid sample:gas interface with a second liquid.
- detecting a characteristic of the substrate in (d) occurs in the second liquid. Detecting a characteristic of the substrate in (d) can take place prior to formation of the liquid sample:second liquid interface. Detecting a characteristic of the substrate in (d) can occur at a location upstream of said junction with respect to the direction of flow of said second liquid.
- detecting a characteristic of the substrate and/or reagent in (e) occurs in the second liquid. Detecting a characteristic of the substrate and/or reagent in (e) can take place after formation of the liquid sample:second liquid interface. Detecting a characteristic of the substrate and/or reagent in (e) can occur at a location downstream of said junction with respect to the direction of flow of said second liquid.
- detection of the characteristic of the contacted liquid sample reagent and/or substrate in (f) occurs in the second liquid. Detection of the characteristic of the contacted liquid sample reagent and/or substrate in (f) can take place after formation of the liquid sample:second liquid interface. Detection of the characteristic of the contacted liquid sample reagent and/or substrate in (f) can occur at a location upstream of said junction with respect to the direction of flow of the second liquid. The detection of this characteristic can involve the detection of an assay result at a detection zone in the second channel portion of the microfluidic device.
- the first and second position are in a second channel portion of the microfluidic device, wherein the first position is in a detection zone for detecting an assay result and the second position is in an overflow channel, e.g. at a reagent control zone.
- the first and second positions are spatially separated in the channel network of the microfluidic device such that following contact with the second liquid mixing, between respective positions, of reagents deposited at or near the respective positions does not occur or is negligible.
- Reagent can be deposited at the first and/or second positions, or adjacent or proximal to the respective position(s). Detection of the characteristic can occur close to the location of deposited reagent and can be at, adjacent or proximal to, the first and second positions. Sensors can be positioned at the respective positions to detect the characteristic.
- a method further comprising the step of comparing a detected characteristic against a reference value.
- a reference value can be a laboratory standard. It can represent a known activity of the substrate or reagent prior to incorporation in the microfluidic device such that a change in the activity of the substrate or reagent following storage in the microfluidic device can be determined.
- the comparison step can therefore provide a control for changes in substrate and/or reagent activity.
- the detected characteristics of the substrate and reagent at the first and second positions can be used as controls for reagent and/or substrate activity, which are useful to determine whether reagents used in the assay have undergone a change in activity (e.g. reduction in activity) which may affect the assay result.
- the control values detected can be used to validate the assay result or adjust the assay result to take account of a change in reagent or substrate activity.
- the method can comprise using the detected characteristics from (d) and (e) to determine a difference in activity of substrate and/or reagent contained in the microfluidic device from a respective reference activity or activities. Determining the difference can involve calculating a difference in activity of substrate and/or reagent contained in the microfluidic device from a respective reference activity or activities. This difference can be used to validate the detected characteristic of the contacted liquid sample reagent and/or substrate, e.g. the assay result. This difference can also be used to adjust a detected characteristic of the contacted liquid sample reagent and/or substrate, e.g. to calculate and apply a correction to the characteristic of the contacted liquid sample reagent and/or substrate. Thus, in some disclosed methods the initial assay result is corrected to provide an adjusted final assay result.
- the step of contacting, within the microfluidic device, reagent with the liquid sample comprises contacting, in the first portion of the channel, reagent and magnetically susceptible particles with the liquid sample, the magnetically susceptible particles forming a complex with the reagent and comprising a binding agent configured to bind an analyte in the liquid sample.
- the method may further comprise the step of magnetically moving magnetically susceptible particle .reagent complexes across the liquid sample:second liquid interface into the second liquid and to a detection zone in the second channel portion.
- the reagent can be, or comprise, one or more enzymes.
- the reagent is horse radish peroxidase and the substrate is ABTS.
- the second liquid can also contain hydrogen peroxide.
- Also disclosed is a method comprising: (a) mobilizing, within a microfluidic device and using a liquid sample, a dry reagent, the liquid sample containing an analyte, (b) subsequently forming, within the microfluidic device, a second liquid-liquid sample interface between a second liquid and the liquid sample, the second liquid comprising a second reagent which is a substrate of the dry reagent; (c) subsequently detecting, at a first position within the microfluidic device, a characteristic of a first amount of the substrate in the second liquid; (d) moving an amount of the mobilized dry reagent and the analyte from the liquid sample into the second liquid to a second position within the microfluidic device, the amount of moved mobilized dry reagent being indicative of the amount of analyte present in the liquid sample; (e) detecting a characteristic of the substrate at the second position; (f) using the characteristics detected in (c) and (e) to validate or adjust the characteristic detected in (e),
- the first amount of substrate is the amount or portion of substrate contained in the second liquid in the region of the reagent control zone and from which the characteristic is detected.
- the characteristic of the first amount of the substrate can be independent of the amount of analyte present in the liquid sample.
- Detection of a characteristic can comprise determination of a characteristic. This may comprise determining, measuring or detecting a signal (quantitatively or qualitatively). The detection can be determining the conversion of one or more substrates into one or more products. In some embodiments detecting a characteristic of the substrate comprises electrochemical detection of oxidized or reduced substrate. This can comprise detection of the oxidation or reduction state of the substrate. In other embodiments it can comprise detection of a fluorescent marker or label.
- a method includes transporting a magnetic or magnetically susceptible particle across an interface between a sample reagent mixture and another medium (e.g., a fluid such as a gas or liquid).
- the particle includes a binder for an analyte or analyte complex.
- the analyte is determined after transporting the particle and bound analyte across the interface.
- At least the step of transporting can be performed in a microfluidic device.
- the method may include introducing a liquid sample to a first portion of a channel of a microfluidic device; contacting, within the microfluidic device, magnetically susceptible particles with the liquid sample, the magnetically susceptible particles comprising a binding agent configured to bind an analyte; forming, proximal to a junction between the first portion of the channel and a second portion of the channel, a liquid sample:gas interface; forming a liquid sample:second liquid interface by displacing gas of the liquid sample:gas interface with a second liquid, and magnetically moving the magnetically susceptible particles across the liquid sample:second liquid interface into the second liquid.
- the method may be a method for detecting an analyte in the liquid sample, the magnetically susceptible particles adapted to bind the analyte wherein the method further comprises the step of detecting analyte in the second liquid.
- the method may be for detecting an analyte and comprise the step of determining an amount of the analyte.
- the method may include separating an analyte from the liquid sample and transporting the analyte into the second liquid.
- the method may be an in vitro method.
- the first and second liquids are typically different.
- the first liquid may be a bodily fluid from a human or mammal (e.g., blood, serum, or plasma).
- the second liquid may be a buffer solution.
- the method may be an in vitro method for detecting an analyte in a liquid sample of blood, plasma or serum from a human comprising introducing the liquid sample to a first portion of a channel of a microfluidic device; contacting, within the microfluidic device, magnetically susceptible particles with the liquid sample, the magnetically susceptible particles comprising a binding agent configured to bind an analyte; forming, proximal to a junction between the first portion of the channel and a second portion of the channel, a liquid sample:gas interface; forming a liquid sample:second liquid interface by displacing gas of the liquid sample:gas interface with a second liquid, and magnetically moving the magnetically susceptible particles across the liquid sample:second liquid interface into the second liquid.
- the method may include determining an assay result.
- the method may include determining an amount of the analyte.
- the method may include comparing the amount of analyte determined against a reference amount to produce an assay result.
- the method may include displaying the determined amount of analyte.
- the method may include displaying information based on an assay result.
- the information may be indicative of the assay result (e.g., may be indicative of the amount of analyte in the second liquid).
- the assay result displayed may be proportional to the amount of analyte in the second liquid.
- Forming a liquid sample:second liquid interface by displacing gas of the liquid sample:gas interface with a second liquid may comprise directing the second liquid across the face of the liquid sample at the liquid sample:gas interface.
- Forming a liquid sample:second liquid interface by displacing gas of the liquid sample:gas interface with a second liquid may comprise directing a flow of second liquid across the face of the liquid sample at the liquid sample:gas interface to decrease an area of the liquid sample:gas interface. During flow of the second liquid across the face of the liquid sample the first liquid may be held essentially static.
- the method may comprise the step of forming a liquid sample .second liquid interface in which substantially no bulk movement of liquid (other than diffusion) occurs across the interface.
- the method may comprise the step of magnetically positioning magnetically susceptible particles at a predetermined detection zone in the second channel portion.
- the method may comprise magnetically moving the magnetically susceptible particles adjacent or upon a sensor located in, or juxtaposed to, the second channel portion of the device.
- the particles may be magnetically retained adjacent or upon the sensor for an amount of time sufficient for the sensor to detect a characteristic of the second liquid.
- the method may include magnetically positioning the magnetically susceptible particles adjacent one or more electrodes configured in the second channel portion to contact the second liquid.
- the method may include detecting a characteristic of the second liquid at the electrode(s).
- the step of detecting a characteristic may comprise detecting an electrochemical signal in the second liquid.
- the magnetically susceptible particles may be held adjacent or upon the one or more electrodes for an amount of time sufficient for the electrodes to detect an electrochemical signal in the second liquid.
- the detection may comprise detecting the presence of analyte in the second liquid.
- the detection may comprise detecting an amount of analyte in the second liquid.
- the step of introducing the liquid sample may comprise depositing a quantity of the liquid sample at an inlet of the device, wherein the inlet is in fluid connection with the first channel portion.
- the method may be a diagnostic method.
- the method is a method for detecting NTproBNP in a liquid sample of blood, plasma or serum from a human and the method includes introducing the liquid sample to a first portion of a channel of a microfluidic device; contacting, within the microfluidic device, the liquid sample with reagents comprising magnetically susceptible particles conjugated to a first anti-NTproBNP antibody, and a second anti-NTproBNP antibody conjugated to an enzyme label, to form complexes comprising magnetically susceptible particle, NTproBNP and enzyme label; forming, proximal to a junction between the first portion of the channel and a second portion of the channel, a liquid sample:gas interface; forming a liquid sample:second liquid interface by displacing gas of the liquid sample:gas interface with a second liquid; magnetically moving the magnetically susceptible particles across the liquid sample:second liquid interface into the second liquid; and detecting NTproBNP in the second liquid.
- the liquid sample:gas interface may be essentially static with respect to movement along the channel between forming the liquid sample:gas interface and forming the liquid sample:second liquid interface.
- the invention relates to a device as set out in independent claim 1.
- one or more of the internal wall(s) of the first channel portion are hydrophobic.
- Proximal to the junction one or more of the internal wall(s) of the first channel portion can have a hydrophobic patch, a hydrophobic line or a hydrophobic ring extending around the circumference of the first channel portion.
- the inlet is partitioned into one or more first compartments in fluid connection with the first channel portion thereby defining a total volume of the first channel portion and first compartments (V i ), and one or more second compartments not in fluid connection with the first channel portion.
- the second channel portion has a liquid overflow channel portion, said overflow channel portion partitioned into a first overflow channel portion proximal the junction and a second overflow channel portion distal to the junction, wherein the reagent control zone is located in the second overflow channel portion.
- the main longitudinal axis of at least one of the first and second overflow portions can be substantially parallel to the first channel portion.
- the main longitudinal axis of at least one of the first and second overflow portions can be substantially parallel to the first channel portion.
- the first portion of the channel has a main channel height h 1 and a channel height h' 1 at the junction, wherein h 1 >h' 1 and wherein at the junction, the first channel portion has height h' 1 and the second channel portion has height h 2 , wherein h 2 >h 1 >h' 1 .
- Proximal to the junction one or more of the internal wall(s) of the first channel portion can be hydrophobic.
- the assay method and device can be used in home testing kits for analyzing species present in the blood.
- the device and method facilitate the performance of more than one assay on a small sample volume, and are suitable for use with home testing kits that use the "finger stick” or "finger prick" procedure.
- the assay device and method can accept small fluid samples in a simple step, and is able to present small fluid samples for immediate testing in a reliable and reproducible fashion.
- the present invention provides an efficient way to utilise obtained blood samples in a home testing kit by allowing the performance of a series of tests on the same sample.
- the device and method facilitate the execution of more than one assay on the same blood sample by separating and isolating analytes of interest, within a complex mixture. This enables the visualisation of the analytes by a detection procedure.
- the present invention affords the use a specific reagent for visualising a marker related to an analyte and the reliable quantification of its presence to inform on a disease state in a subject.
- Embodiments permit determination of one or several analytes, such as analytes indicative of disease states in a subject, to be detected.
- the invention includes the combination of the described aspects and features except where such a combination is clearly impermissible or expressly excluded.
- Typical analytes are biomarkers related to (e.g., indicative of) the presence of a physiological condition in a mammalian subject.
- the presence of the physiological condition can be determined based at least in part on the result of the determination of the biomarker (e.g., by comparing the result to a reference value).
- the assays can be for use in reaching a diagnosis or prognosis.
- Assay methods can comprise methods of diagnosis or prognosis of a pathological condition or disease state in a user or susceptibility of the user to a pathological condition or disease state.
- the assay device can be provided for use in a method of diagnosis or prognosis of a pathological condition or disease state in a user or susceptibility of a user to a pathological condition or disease state.
- the assay method is an in vitro method not practised on the human or animal body.
- the assay method is practised on a liquid sample which may be a sample collected from the human or animal body, e.g. a bodily fluid sample such as a human blood sample.
- the sample is used to conduct the assay and is then discarded, and is not returned to the human or animal from which it was collected.
- magnetically susceptible particles are used in the capture of an analyte, the separation of an analyte from a liquid sample, and in the positioning of the analyte proximal a detection zone.
- an analyte is separated from a liquid sample. After being separated, the analyte is detected in a second medium (e.g., another fluid (e.g., a gas such as air, a different liquid such as a buffer) or flowable medium (e.g., a gel, such as an electrophoresis gel).
- a second medium e.g., another fluid (e.g., a gas such as air, a different liquid such as a buffer) or flowable medium (e.g., a gel, such as an electrophoresis gel).
- An exemplary method includes combining magnetically susceptible particles adapted to bind the analyte with the liquid sample to form complexes of magnetically susceptible particle bound analyte. The complexes are magnetically separated from the liquid sample into the second medium.
- Separation of the complexes from the liquid sample into the second medium is typically achieved by a method that includes forming an interface between the liquid sample and second medium.
- the interface is stable, and essentially static (i.e. diffusion may occur with respect to the interface but the position of the interface is essentially constant).
- the position of the interface relative to the microfluidic device may be essentially constant (e.g., the relative position may change by about 5 mm or less, about 2.5 mm or less, about 1 mm or less) at least prior to the transport of the magnetically susceptible particles across the interface as described below.
- the position of the interface is essentially constant at least prior to determination of the analyte.
- the interface is typically substantially free of gas bubbles.
- it can be free of gas bubbles or may contain a small number of gas bubbles that do not prevent transfer across the interface of substantially all of the magnetically susceptible particles clustered in the liquid sample adjacent the interface, wherein substantially all of the magnetically susceptible particles is at least about 70% (e.g. at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%) of the clustered magnetically susceptible particles.
- the interface is formed between the liquid sample and the second medium (e.g., another fluid (e.g., a gas such as air, a different liquid such as a buffer) or flowable medium (e.g., a gel, such as an electrophoresis gel)).
- the interface is defined by the contacting parts of the liquid sample and the second medium.
- a magnetic field is applied to the magnetically susceptible particle:analyte complexes in the liquid sample and the complexes are magnetically moved towards the liquid sample:second medium interface.
- the magnetic field moves the complexes across the interface and into the second medium. The transport across the interface separates the complexes from the liquid sample.
- movement of substantially all of the magnetically susceptible particle:analyte complexes across the liquid sample:liquid interface is optimized by controlling the speed of movement of the magnetic field towards the interface, and across the interface.
- the timing of movement of the magnetically susceptible particle:analyte complexes across the interface can be controlled to be coincident with, or very shortly after, formation of the liquid sample:second liquid interface.
- the complexes can be further magnetically moved to a sensor (e.g., an electrochemical sensor including one or more electrodes), where the presence of analyte can be detected directly or indirectly.
- a sensor e.g., an electrochemical sensor including one or more electrodes
- an indirect detection is performed wherein the complexes include an enzyme label capable of producing a detectable reaction in the presence of one or more enzyme substrates and/or cofactors.
- the enzyme may produce a product such as an oxidized or reduced enzyme substrate, cofactor or byproduct.
- the product can be detected electrochemically using the electrochemical sensor.
- the electrochemical sensor may include one or more electrodes in contact with the second medium.
- the separation of analyte from the liquid sample is desirable as the presence of analyte can then be detected without interference from contaminants (e.g., molecular components such as biological compounds) of the liquid sample.
- contaminants e.g., molecular components such as biological compounds
- some liquid samples e.g. blood
- separation of analyte from blood may be desirable in order to accurately determine the presence of the analyte.
- a device is provided to perform the method of detecting an analyte.
- the method of detection is an assay for the presence of analyte in the liquid sample and the device an assay device for that method.
- the assay device is a microfluidic device having a channel network.
- the network comprises an inlet connected to a first channel portion, which is connected to a second channel portion at a junction (e.g., a capillary stop) at an intermediate position in the channel network.
- a junction e.g., a capillary stop
- the second channel portion can have a cross-sectional area that is larger than the first channel portion creating a capillary stop pressure (p capstop ) and forming the capillary stop.
- the capillary stop can alternatively be formed by other means, such as the use of a hydrophobic patch disposed on one or more interior surfaces of the channel.
- Liquid sample deposited at the inlet can flow into the first channel portion and fill the first channel portion up to the junction.
- Liquid sample forms an interface (e.g., a liquid sample:second medium interface) proximal to the junction of the first and second channel portions.
- the second medium is typically another fluid (e.g., a gas such as air, a different liquid such as a buffer) or flowable medium (e.g., a gel, such as an electrophoresis gel).
- the second medium is a gas and the interface is a liquid sample-gas interface (e.g., a meniscus).
- the interface is formed by contacting a first interface between (a) one of the liquid sample and the second medium and (b) third medium with the other of the liquid sample and the second medium such that the other of the liquid sample and the second medium displaces the third medium from the first interface.
- the third medium is a second liquid (e.g., a buffer) and the device further includes, or is configured to cooperate with, a reservoir of second liquid from which second liquid can be released into the second channel portion to flow towards the junction (e.g., towards the interface).
- the second channel portion directs released second liquid to the liquid sample:gas interface to displace the gas (e.g., air) and form a liquid sample:second liquid interface.
- the region of the second channel portion adjacent the junction is configured to direct second liquid transversely across a face of the liquid sample:air interface to progressively decrease the area of the liquid sample:air interface as the second liquid flows across the face of the liquid sample:air interface.
- the interface may be essentially static and/or bulk movement of liquid relative to the interface may be absent at least until transport across the interface as described above.
- the configuration of the second channel portion adjacent the interface can include a change in height and/or width of the second channel portion.
- the configuration of the second channel portion adjacent the interface includes a tapering of the width and height of the second channel portion to increase the second channel portion width and height at the junction.
- the second channel portion can further include a change of direction proximal to the junction provided by a bend portion in the second channel portion adjacent the junction.
- An inside wall of the bend portion can further comprise a capillary stop (e.g. a notch or vent in the inside wall and/or a hydrophobic patch), whilst an outside wall of the bend does not have a corresponding capillary stop.
- Second liquid advancing towards the junction is retarded at the capillary stop on the inside wall of the bend such that the second liquid advances more rapidly around the outside wall of the bend, in which the junction of the first and second channel portions can be located (at least partially).
- the portion of second liquid adjacent the outside wall pivots with respect to the capillary stop. This directs the flow of second liquid transversely across the face of the liquid sample:air interface formed at the junction and facilitates formation of a liquid sample:second liquid interface that is substantially free of air bubbles.
- Reagents in the first channel portion form magnetically susceptible particle:analyte complexes with analyte in the liquid sample. These complexes can now be magnetically moved across the liquid sample:second liquid interface and towards a sensor, e.g. one or more electrodes, in the second channel portion where the presence of the analyte can be detected.
- a sensor e.g. one or more electrodes
- the device is configured for operation in conjunction with a meter or reader into which the device is inserted.
- the meter includes a magnet, which may be an electromagnet, for magnetically moving the magnetically susceptible particles and complexes.
- the meter also includes components configured to receive signals from the assay device, and a processor and display for determining and displaying an assay result.
- the device can be configured to detect more than one analyte.
- analytes are biomarkers related to (e.g., indicative of) the presence of a physiological condition in a mammalian subject.
- the presence of the physiological condition is determined based at least in part on the result of the determination of the biomarker (e.g., by comparing the result to a reference value). Determination of an analyte can be direct or indirect.
- an analyte can be indirectly determined by detecting a signal (e.g., an electrochemical or optical signal) resulting from a detectable label (e.g., an enzyme label) conjugated to the analyte.
- a detectable label e.g., an enzyme label
- An analyte can be directly determined by, for example, detecting a signal (e.g., an electrochemical or optical signal) resulting from the analyte itself.
- any of the devices or methods described herein can be further configured or implemented to perform at least one action at least in part based on and/or using a result of the determination.
- the at least one action can be selected from the group consisting of storing the result, making the result available for further processing, displaying the at least one result, recording the result, transmitting the result to a remote location, comparing the result to a reference value, displaying information related to the result, choosing from among multiple actions based on the result, or combination thereof.
- the term "result" includes values or indicia indicative of the result.
- an assay may result in the detection or determination of a characteristic or the detection of an analyte.
- the result of the determination or detection may be further stored, and/or processed and/or recorded and/or transmitted to a remote location and/or compared to a reference value (e.g. a standard subject population reference value or an individual subject reference value (e.g., a baseline determined from one or more prior determinations of the analyte from the patient)) and/or displayed as an assay result (e.g. to a user of the apparatus) and/or acted on (e.g. through the alteration of a therapeutic programme or strategy).
- Transmission of a determination or detection to a remote location can be carried out by a communications network, e.g. LAN, WAN, and may be via the internet. Transmission can be wireless transmission to a server, host or proxy. Wireless transmission can be implemented using the Bluetooth® transmission protocol.
- the analyte may be any analyte, and more particularly any analyte to which a binding agent, such as an antibody, may be raised and coupled to a magnetically susceptible particle.
- an analyte is a natriuretic peptide such as at least one of BNP or NT-proBNP.
- NT-proBNP N-terminal truncated pro-brain natriuretic peptide
- BNP is the 32 amino acid (aa) peptide cardiac hormone synthesized by ventricular cells and stored as a 108aa pro-peptide. It is secreted in response to ventricular expansion or pressure overload.
- the pro-peptide is cleaved to release the 32aa active BNP and a 76aa N-terminal fragment (NT-proBNP).
- BNP and NT-proBNP are markers of ventricular distension and overload.
- NT-proBNP is correlated with ambulatory cardiac filling pressures in outpatients with chronic heart failure ( Braunschweig et al., European Journal of Heart Failure 8 (2006) 797-803 ) and is indicated as a biomarker of myocardial stretch and chronic heart failure ( Murdoch et al., Am Heart J 138(6):1126-1132, 1999 ) and as a predictor of mortality in acute heart failure ( Sakhuja et al., Clinical Chemistry 53:3 412-420 (2007 ).
- Exemplary assays for determining a concentration or amount (qualitative or quantitative) of NT-proBNP in a human blood sample can therefore be used in the monitoring, diagnosis, prognosis, assessment of risk of, and/or assessment of susceptibility to a pathological condition or disease wherein, for example, the pathological condition or disease is chosen from a cardiac condition or disease; heart failure; chronic heart failure; congestive heart failure; myocardial infarction; hypertension.
- the analyte can be chosen from potassium ion, cystatin C, troponin T, troponin I, myeloperoxidase, creatine kinase MB.
- the analyte can be a biomarker for a condition that afflicts the mammalian body.
- biomarker refers to a biochemical in the body that has a particular molecular trait to make it useful for diagnosing a condition, disorder, or disease and for measuring or indicating the effects or progress of a condition, disorder, or disease.
- biomarkers found in a person's bodily fluids i.e., breath or blood
- the respective diagnostic conditions of the person providing such biomarkers include, but are not limited to, ischemia modified albumin "IMA” (source: lack of oxygen to the blood; diagnosis: coronary artery disease), N-terminal truncated pro-brain natriuretic peptide "NT pro-BNP” (source: stretching of myocytes; exemplary diagnosis related to congestive heart failure), acetaldehyde (source: ethanol; diagnosis: intoxication), acetone (source: acetoacetate; diagnosis: diet; ketogenic/diabetes), ammonia (source: deamination of amino acids; diagnosis: uremia and liver disease), CO (carbon monoxide) (source: CH 2 Cl 2 , elevated % COH; diagnosis: indoor air pollution), chloroform (source: halogenated compounds), dichlorobenzene (source: halogenated compounds), diethylamine (source: IMA” (
- the biomarker can be a marker of heart failure (e.g. chronic heart failure, heart disease or susceptibility to myocardial infarction (MI), e.g. a marker of MI risk) or a renal marker, e.g. a marker of glomerular filtration rate, which may provide information on blood volume.
- MI myocardial infarction
- a renal marker e.g. a marker of glomerular filtration rate
- the sample material is a liquid such as a biological liquid (e.g., blood, blood plasma, serum, urine, saliva, mucous, tears, semen, cerebrospinal fluid (CSF), lymph or other bodily fluid).
- a biological liquid e.g., blood, blood plasma, serum, urine, saliva, mucous, tears, semen, cerebrospinal fluid (CSF), lymph or other bodily fluid.
- the sample material is a bodily fluid from a mammal (e.g. a human who may be male or female).
- the sample material is whole blood from a human.
- the analyte can be any component that is found (or may potentially be found) in the sample, such as, for example, a protein, a peptide, a nucleic acid, a metabolite, a saccharide or polysaccharide, a lipid, a drug or drug metabolite, or other component.
- the assay device can optionally be supplied with a blood separation membrane arranged between a sample inlet and the detection zone, such that when whole blood is available as a sample, only blood plasma reaches the detection zone.
- Magnetically susceptible particles can include magnetic particles or particles that can be manipulated (e.g., moved) and/or positioned by a magnetic field.
- the magnetically susceptible particles can be non-magnetic but susceptible to manipulation or positioning by a magnetic field or be magnetic (e.g. a source of a magnetic field lines).
- the magnetically susceptible particles can be spherical beads and can have a diameter of at least about 0.05 microns, at least about 1 micron, at least about 2.5 microns, and typically less than about 20 ⁇ m.
- a magnetically susceptible particle can be, for example, a magnetic particle described, in U.S. Patent Application Publication Nos. 20050147963 or 20050100930 , or U.S. Patent No.
- 5,348,876 or commercially available beads, for example, those produced by Dynal AS (Invitrogen Corporation, Carlsbad, California USA) under the trade name DYNABEADSTM and/or MYONETM.
- antibodies linked to magnetic particles are described in, for example, United States Patent Application Nos. 20050149169 , 20050148096 , 20050142549 , 20050074748 , 20050148096 , 20050106652 , and 20050100930 , and U.S. Patent No. 5,348,876 .
- the magnetically susceptible particles may be ferrous particles.
- the magnetic field to which the particles are susceptible can be applied by a magnet, which can be any kind of magnet including a permanent magnet, temporary magnet, or electromagnet.
- the magnet can be used as a magnetic source for application of a magnetic field towards magnetically susceptible particles.
- components or Iiquid:gas or liquid:liquid interfaces can be positioned proximal to a physical structure.
- Proximal positioning refers to positioning close to the physical structure. The positioning can be at, or adjacent, the physical structure.
- Exemplary embodiments include a microfluidic device.
- a microfluidic device can comprise a support in which one or more channels are formed to provide a channel network capable of directing flow, and optionally controlling flow, of liquid through part or all of the network. Typically the channel network will have multiple channel portions.
- the microfluidic device is configured to perform a desired assay, and can be configured to interact with a meter in order to provide an assay result.
- the microfluidic device is generally small enough to fit on a laboratory bench, and in exemplary embodiments is small enough to be carried by an individual human user in one or two hands.
- channels and channel portions are generally enclosed spaces defined by surrounding walls.
- the channel can have any cross-sectional shape (e.g. rectangular, trapezoidal, or circular).
- Channels can be in fluid communication with the atmosphere external to the microfluidic device by means of apertures (e.g., inlets, outlets or vents) formed in the channel network.
- Channels or channel portions can be open to the atmosphere for part or all of their length, e.g. by not having an enclosing lid.
- Channels or channel portions can comprise a capillary, i.e. a channel of small internal diameter capable of holding or transporting liquid by capillary action, wherein capillary action is (at least in part) the effect of surface tension that draws a liquid into or along the channel.
- Devices can be for use in performing an assay, e.g. on a blood sample.
- the user can be a human (male or female).
- the user can perform the assay in the absence of the presence, or in-person assistance, (verbal or otherwise) of a medical practitioner (e.g. nurse, physician, medical doctor, general practitioner, surgeon or phlebotomist).
- a medical practitioner e.g. nurse, physician, medical doctor, general practitioner, surgeon or phlebotomist
- the assay devices can be configured for use away from the hospital, doctor's office, surgery or other medical establishment and can be used in a domestic environment, such as the home or office, or in any convenient location.
- a method and/or device and/or meter can be configured for conduct of an assay and production of an assay result to a user in a total test time of less than about 30 minutes (e.g. less than about 20 minutes, less than about 15 minutes, less than about 10 minutes) and in one embodiment in about 10, 11 or 12 minutes.
- one or more sensors can be used to determine a characteristic of a liquid and/or to detect a signal.
- the signal can be the presence or absence of a component, e.g. analyte or oxidized compound.
- the sensor is an electrochemical sensor including one or more electrodes and the signal is an electrochemical signal (e.g., a signal formed by the reduction of an oxidized compound at an electrode, or the oxidation of a reduced compound at an electrode), which can be detected and/or measured amperometrically and/or voltametrically at the electrode(s).
- Other sensors include detectors of radiation (e.g. light, X-ray, ⁇ -ray radiation) and/or optical (e.g., fluorescence, reflectance, or absorbance).
- components can be bound or conjugated to one another to form complexes (e.g. a magnetically susceptible particle can be conjugated to a binding agent). Binding or conjugation of components can be direct (e.g. binding of an analyte to an anti-analyte antibody) or indirect (e.g. binding of a magnetically susceptible particle to a binding agent through linkers such as streptavidin and biotin).
- binding agents are molecules capable of specifically binding to a selected target with high affinity, having a K d for the target of about 100 ⁇ M or less (e.g. less than about 50 ⁇ M, less than about 10 ⁇ M, less than about 1 ⁇ M, less than about 100nM, less than about 10nM, less than about 1nM, less than about 100pM, less than about 10pM).
- the first and second binding agents can be respectively chosen from an antibody (monoclonal or polyclonal), antibody fragment (e.g. scFV fragment), antibody binding domain, aptamer or other recognition reagent.
- the first and second binding agents can be different, e.g. an antibody and an aptamer.
- reagents are provided in an assay device (e.g., in dry form).
- the reagents can be configured to participate in an assay, e.g. to detect presence of analyte, and can be configured to form conjugates and/or bind the analyte.
- the reagents include conjugates of magnetically susceptible particle and at least one reagent (e.g., an antibody labeled enzyme) configured to bind the analyte and form a ternary complex with the magnetically susceptible particle.
- conjugates of magnetically susceptible particle and reagents are configured to participate in a sandwich assay involving first and second binding agents to form a ternary complex.
- Exemplary embodiments provide a device and method for performing an assay on a single small volume blood sample, or other biological materials or complex mixtures.
- an assay method 1000 includes a mixture formation step 1001, a reagent/analyte capture step 1002, a complex transport step 1003, a complex determination step 1004 and a formation of an assay result step 1005.
- method 1000 is performed using an assay device including a reagent zone, in which the sample reacts with the reagents, a detection zone in which determination of the analyte is performed (either qualitatively or quantitatively), and an interface zone, which provides an interface between the reagent zone and the detection zone.
- mixture formation step 1001 a mixture including a quantity of sample material (e.g. a sample liquid such as blood from a human) and reagents capable of binding to an analyte is formed.
- the reagent capable of binding to the analyte may be an antibody or antibody domain or fragment (e.g. scFv) capable of binding to the analyte.
- reagent/analyte capture step 1002 the reagents capable of binding the analyte form complexes with analyte that is present in the sample.
- complex transport step 1003 reagent:analyte complexes formed during the previous step may be washed to remove non-complex material and are transported to a detection zone.
- the presence of reagent:analyte complexes that have been transported to the detection zone is determined (e.g. qualitatively or quantitatively).
- the assay result is formed in step 1005 as a result of the extent of detection of reagent:analyte complexes in the preceding step.
- detection of reagent:analyte complexes may be indicative of the diagnosis or prognosis (new or continued) of a disease state or pathological condition of a user or patient. Therefore, the detection of reagent:analyte complexes may be used or processed (e.g. by comparison with a reference value), to provide an assay result, which may be displayed to the user.
- mixture formation step 1001 a mixture is formed between reagent materials that are disposed within a reagent zone of an assay device and a quantity of sample material sufficient to fill the reagent zone of the assay device.
- a sample of blood can be obtained from a finger stick or a venous puncture.
- the volume of blood is typically about 10 ⁇ l or about 5 ⁇ l.
- the reagents typically include the following species; magnetically susceptible particles, a first reagent capable of binding to the analyte, a second reagent capable of binding to the analyte concurrently with the first reagent (e.g., as in a sandwich).
- the reagent binds to a first unique region of the analyte and the second reagent binds to a second unique region of the analyte.
- the first reagent is configured to bind to the magnetically susceptible particles even in the absence of analyte (e.g., in a non-specific binding reaction).
- the first reagent may include a biotin portion and the particle may be coated with streptavidin, which captures the biotin modified first reagent.
- the second reagent includes a detectable label (e.g., an enzymatic label such as an enzyme).
- the second reagent is a labeled particle (e.g., a non-magnetically susceptible particle such as a colloidal gold sol particle) that is conjugated with a binding reagent for the analyte (e.g., an antibody for the analyte) and with an enzymatic label.
- the particle includes multiple enzymatic labels thus increasing the number of enzyme labels that become part of the reagent:analyte complex.
- the second antibody-enzyme conjugate is typically provided pre-associated with the labeled particles.
- the first and second recognition reagents do not associate with one another in the absence of analyte.
- the presence of analyte can associate the first and second recognition reagents together, in a ternary complex
- the second reagent can recognize the same or a different analyte and can be a binding agent that specifically binds the same or a different analyte.
- the reagent zones can include further reagents such as redox mediators, substrates for particular enzymes and salts suitable for forming buffer solutions.
- the second binding agent can be linked to a particle that can induce mobility on the so-formed ternary complex.
- the particle can be, for example, a polymer microsphere, a metal nanoparticle, or a magnetically susceptible particle.
- each complex may include multiple analyte molecules and multiple second reagents.
- the reagent zone may include one or more additional reagents such as, for example, an anti-coagulant to inhibit clotting of blood within the reagent zone and/or buffer salts.
- Buffer salts present in the reagent zone control the pH of the mixture to give a pH value that favours the formation of complexes.
- the pH value is maintained at a desired pH, for example the pH may be maintained within a range of between about pH 7.2 and about pH 7.6.
- Reagent/analyte capture step 1002 includes forming complexes between the reagents and analyte contained within the sample.
- the dried reagents initially form an inhomogeneous mixture with the sample.
- the reagents become sufficiently hydrated that they begin to interact with the sample.
- the first and second antibodies bind to analyte and form complexes.
- the biotin labeled first reagent binds to the streptavidin coated magnetically susceptible particle(s).
- the second reagent e.g., a non-magnetically susceptible particle conjugated to an enzyme label and a binding agent for the analyte
- Complex transport/wash step 1003 includes moving the reagent:antibody complexes from the reagent zone to the detection zone.
- the detection zone is filled (e.g., actively) with a buffer solution during the course of a sample assay. Buffer is released from a reservoir at a predefined time after sample has been applied to the assay device. Buffer solution fills the detection zone and the interface zone. When buffer solution is delivered into the interface zone, the buffer forms a sample liquid:second liquid interface with the sample in the reagent zone (as will be described in more detail below). Excess buffer solution moves in to an overflow channel. When buffer has made contact with and formed an interface with the
- the reagentranalyte complex can thus be moved along the length of the assay device supported in a continuous liquid stream.
- a magnetic field can be used to manipulate the reagent:analyte complex within the assay device.
- the reagent:analyte complex can be drawn along the reagent zone, through the interface zone to the detection zone by a magnetic field.
- the path of the magnetic field moves in a direction that transfers magnetically susceptible particle complexes from the reagent zone to the detection zone.
- one or more of the detection zones include one or more electrodes.
- the electrodes can be formed of a material selected for electrical conductivity and low reactivity with sample components, for example, silver, gold, aluminum, palladium, platinum, iridium, a conductive carbon, a doped tin oxide, stainless steel, or a conductive polymer.
- the electrodes in the detection zones (the working electrodes), in conjunction with second electrodes in the reference zones (the reference electrodes) can measure an electrical property of the sample, such as a voltage or a current.
- the detection zones and the reference zones can each have at least one working electrode and counter electrode. That is, the detection and reference zones can make independent measurements.
- counter electrodes are also included in the assay device. Assay devices including electrodes for measuring electrical properties of a sample are described in, for example, U.S. Patent Nos. 5,708,247 , 6,241,862 , and 6,733,655 .
- the assay device base, assay device lid, or both have a translucent or transparent window aligned with the detection zone.
- An optical change that occurs in the detection zone can be detected through the window. Detection can be done visually (i.e., the change is measured by the user's eye) or measured by an instrument (e.g., a photodiode, photomultiplier, or the like).
- the reference zone is similar in nature to the detection zone. In other words, when the detection zone includes an electrode, the reference zone can likewise include an electrode. When the detection zone is aligned with a window for optical measurement, the reference zone can similarly be aligned with a window for optical measurement. In some embodiments, the reference zone is not adapted to collect analyte.
- the reference zone is adapted to collect analyte, but performs a different analysis on said analyte.
- the detectable change measured in the reference zone can be considered a background measurement to be accounted for when determining the amount or concentration of analyte present in the sample.
- magnetically susceptible reagent:analyte complexes that have been transferred to the detection zone can be measured.
- the detection zone includes electrodes that can be used to perform an electrochemical analysis of the sample.
- the enzyme labeled second reagent that is part of reagentranalyte complex can convert a substrate present in the buffer used to fill the detection zone.
- the substrate can be converted from a first form that is not detectable to a second form that is detectable.
- a measurement electrode within the detection zone can be used to measure the detectable form of the substrate. For example, an amperometric measurement can be made, in which a working electrode is polarised at a certain potential versus a reference electrode e.g.
- a silver/silver chloride (Ag/AgCl) reference electrode For example, potassium ferricyanide can be converted (reduced) to potassium ferrocyanide by glucose oxidase during the conversion of glucose to gluconic acid. Any potassium ferrocyanide formed can be measured at about +400 mV vs Ag/AgCl as a positive current. The ferrocyanide is re-oxidised back to ferricyanide by the working electrode. An electroactive species can be oxidised, in which case it loses electrons to the electrode, or reduced, in which case it receives electrons from the electrode. The transfer of electrons between the electrode and the electroactive substance results in a measurable current, which may be a positive or negative current.
- An amperometric measurement of an electroactive substance can be used to construct a calibration line.
- the buffer contained within the reservoir of the assay device includes a buffer salt and a substrate for the enzyme.
- the buffer salt buffers the pH to provide an environment suitable for the enzyme to convert the substrate to a product which can be detected.
- the buffer salt may be an acetate buffer (e.g., sodium acetate).
- the buffer can include at least about 100 mM sodium acetate (e.g., at least about 110 mM sodium acetate).
- the buffer solution can also contain a chloride salt to stabilise the electrochemistry of the reference electrode during analysis (e.g. potassium chloride (KCl)).
- the chloride salt can include at least about 100 mM KCl (e.g. at least about 125mM KCl).
- the buffer solution can also include a detergent to reduce the likelihood of antibody complexes from adhering to the internal surfaces of microfluidic network 508.
- the buffer solution includes 0.1% (v/v) Tween-20TM.
- the buffer also includes substrate(s) for the enzyme label, which in the case of horse radish peroxidase is 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) and hydrogen peroxide (H 2 O 2 ).
- ABTS 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid
- H 2 O 2 hydrogen peroxide
- the buffer contains at least about 5mM ABTS and at least about 5mM H 2 O 2 .
- the enzyme label that is conjugated to second binding agent can be horse radish peroxidase (HRP), for example.
- HRP catalyses the conversion of hydrogen peroxide and ABTS to water and oxidised-ABTS.
- Any oxidised-ABTS that is produced can be measured electrochemically at a working electrode. Therefore during complex determination step 1004 any reagent:antibody complexes that have been transported through the microfluidic network of assay device can be measured according to the amount of oxidised-ABTS that is produced in the proximity of a measurement electrode.
- the measured current is proportional to the amount of oxidised-ABTS according to Eq. 2 and hence the measured current is proportional to the amount of analyte in the complexes that have been transported to the electrode.
- the measurement result obtained during complex determination step 1004 is used to determine an assay result.
- the assay result comprises displaying or communicating a value or signal indicative of the amount or concentration (quantitative or qualitative) of analyte detected in the assay.
- the assay result comprises determining the status of the user, as regards the analyte. Depending on the analyte under investigation an elevated measurement result can indicate a diagnosis or prognosis for a disease state or pathological condition associated with the analyte.
- a user of the assay device can be presented with information. If the user is qualified to make a clinical judgment (such as a medical doctor) the information might be different compared with a non qualified person, such as a user performing a self-test measurement.
- a health care professional will typically want numerical data that will facilitate a prognosis or provide a diagnosis.
- An end user will typically want reassurance that "the way they feel" is a consequence of (i) an unrelated issue, e.g. indigestion or (ii) occurrence or re-occurrence of heart failure, in which case they will be prompted to dial 911, for example.
- the assay device is a microfluidic device in which a channel network is formed.
- the device has a base 502 that can be formed from a plastics substrate, such as polycarbonate in which the channel network can be formed by techniques well known to persons skilled in the art such as moulding, laser ablation or milling of the substrate (as described above).
- the device has a laminate structure (as shown in Fig.6 ) being made up of multiple layers.
- the microfluidic network is defined by a three layer laminate in which a first substrate layer 502 is joined to a third substrate layer 506 by a second substrate layer 504 comprising an adhesive strip, as described above.
- a further adhesive strip joins the third substrate layer 506 with a packing piece 3502 to form a device having five laminate layers.
- the packing piece has a cut-out section 3511 configured to permit a magnet in meter 400 to be positioned in close proximity with the external surface of the third substrate layer 506.
- the first substrate layer 502 further comprises a raised annulus 3510 having a liquid inlet 520 proximal its centre and a sharp projection 3506 positioned at or adjacent the inlet.
- An O-ring seal 2402 is seated on or adjacent the annulus and a liquid containing reservoir 507 is received in the annulus, a wall of which is positioned adjacent the sharp element or projection 3506.
- the sharp projection 3506 is formed as part of the substrate 502.
- the projection 3506 has a pyramid structure the apex of which forms the sharp point 3506 which facilitates puncture of reservoir 507.
- the sharp projection is an integral part of substrate 502 and both may be moulded from plastics material.
- the sharp projection is located adjacent liquid inlet 520, wherein the entrance to liquid inlet 520 is formed by an aperture in one side of the pyramid structure.
- Projection 3506 projects into the centre of the space defined by the raised annulus 3510 and towards a base wall of the reservoir 507 when received in the annulus.
- the sharp projection 3506 can be made of metal (e.g. steel) or plastics material.
- the reservoir 507 is a pouch having a wall, e.g. a base wall, that may be ruptured by sharp projection 3506 on the assay device 500.
- the base wall has a generally smooth outer surface which may be generally planar or convex.
- a seal or gasket e.g. an O-ring seal
- an internal diameter sufficient to encompass the sharp projection and inlet 520 (e.g. at least about 1.5mm, at least about 2mm, at least about 3mm, less than about 5mm, less than about 4mm) is formed or placed around the sharp projection 3506 such that when the reservoir 507 is compressed against the assay device and toward the sharp projection 3506 a gas-tight seal is formed between the reservoir and the assay device preventing air from entering the assay device via the inlet 520 such that liquid in the second channel portion 4304 is substantially free of air or other gas bubbles.
- seal 2401 is integrally formed with the substrate 502 and is a raised circular ridge encompassing the sharp projection 3506 and liquid inlet 520.
- buffer pouch 507 is pushed towards the sharp projection 3506 so as to rupture the buffer pouch and release liquid.
- the surface of the buffer pouch 507 adjacent the sharp projection is urged against seal 2401 to form an air-tight seal around the sharp-projection 3506.
- the liquid forced from buffer pouch 507 and entering inlet 520 is therefore substantially free of air, or gas bubbles. Accordingly, a slug of liquid is forced into second channel portion 4304 and towards the junction 4305.
- the absence of air, or large gas bubbles, in the slug of liquid helps form a stable liquid:liquid interface at junction 4305 and provides for high performance electrochemical detection at the working electrode.
- the reservoir 507 is made from plastics and/or metal foil material and sealed to form a pouch, bag or sachet containing liquid, e.g. buffer liquid.
- the reservoir 507 can be made from first and second materials, wherein one of the materials is softer and/or thinner than the other, the softer or thinner material forming at least part of the wall that is configured for rupture by the sharp projection 3506 on the assay device 500.
- the reservoir 507 has a volume of about 40 ⁇ l (e.g. at least about 50 ⁇ l, at least about 60 ⁇ l, less than about 100 ⁇ l).
- the reservoir 507 is made from a first material (e.g. plastics material) and a second material (e.g. metal foil such as aluminium foil).
- the reservoir is dome-shaped having an upper convex part formed by the first material and a lower planar part made from the second material and forming the base of the dome.
- the planar part is thin (e.g. at least about 20 ⁇ m thickness) and can be punctured when forced towards the sharp projection.
- the lower planar part is positioned adjacent the sharp projection.
- Application of force to the upper convex part forces the lower planar part and sharp projection together, rupturing the reservoir and releasing fluid into inlet 520.
- the lower planar part is pushed against the seal located around the sharp projection and inlet to prevent air mixing with fluid entering inlet 520.
- an exemplary embodiment of the device has an inlet 510 at one end of the strip, the inlet 510 is connected to the channel network 508 such that sample liquid received at the inlet can enter the channel network.
- the channel network 508 has a first channel portion 4302 forming a reagent zone.
- the first channel portion 4302 is connected directly to the inlet 510.
- an inlet channel 4303 connects the inlet 510 and first channel portion 4302.
- the first channel portion 4302 is connected to a second channel portion 4304 at a junction 4305.
- the plane of the junction is substantially orthogonal to the main longitudinal axis of the second channel portion.
- the first and second channel portions can have a common longitudinal axis.
- the first channel portion 4302 is generally rectangular in cross-section, although it may have a different cross-sectional shape, e.g. circular.
- the first channel portion 4302 has a cross-sectional area A 1 which is less than the cross-sectional area A 2 of the second channel portion 4304 at the junction 4305.
- the difference in cross-sectional area of the first and second channel portions at the junction 4305 provides a capillary stop 530, as described above.
- a liquid sample deposited at inlet 510 flows into first channel portion 4302 (e.g. by capillary action) and on reaching the capillary stop 530 the liquid sample meniscus forms a liquid sample:air interface with air contained in the second channel portion.
- the interface is positioned proximal the junction 4305.
- Cross-sectional area A 1 is at least about 0.375mm 2 and A 2 is about 4.67mm 2 .
- the ratio of A 1 :A 2 is about 1:12.
- the second channel portion adjacent the junction 4305, has a tapered neck region 4306 in which the width and height of the second channel portion 4304 increases when moving along the second channel portion from the liquid inlet 520 towards the junction 4305.
- the tapered neck region 4306 provides an increase in the width of the second channel portion from width w6 distal to junction 4305 to width w5 at the junction 4305 and an increase in the height of the second channel portion from height h3 distal to the junction 4305 to height h2 at the junction 4305.
- the tapered neck region 4306 of the second channel portion further comprises a bend portion in which the flow path defined by the second channel portion 4304 is changed from a direction that is substantially toward the junction 4305 to one that is substantially across the junction 4305.
- the bend portion is formed by an inside wall 4307 and an outside wall 4308 of the second channel portion 4304.
- the outside wall 4308 contains a corner 536 and the inside wall 4307 has a means 532 to retard the flow of liquid towards the junction 4305.
- the means 532 can be a capillary stop.
- the outside wall 4308 also comprises, at least partially, the junction 4305 of the first and second channel portions.
- the base of the second channel portion has a slope or chamfer 534 which connects a region 4309 of the second channel portion 4304 that is distal to the junction 4305 and has height h3 with a region 4310 of the second channel portion 4304 that is proximal the junction 4305 and has height h2, wherein h2>h3.
- the slope 534 extends obliquely across the second channel portion from a region proximal the capillary stop 532 towards the opposing channel wall and corner 536.
- the upper edge of slope 534 extends from a region proximal the capillary stop 532 at the inside wall 4307 of the bend portion across the second channel portion 4304 slanting forwards towards the junction 4305.
- the upper edge of slope 534 extends from the region near the capillary stop 532 obliquely forwards towards the junction 4305 and towards a region of the second channel portion having a greater width.
- the lower edge of slope 534 contacting the region 4310 of second channel portion 4304 having height h2 makes an angle of about 20° (e.g. at least about 15°, at least about 30°, at least about 35°, less than about 45°, less than about 40°) with the plane of junction 4305.
- the oblique direction of the slope across the second channel portion towards the junction can thus also be described as an oblique slant of about 70° (e.g.
- the upper edge of slope 534 (distal to junction 4305) at its most distal from the junction, and in the region of capillary stop 532, is about 2.5mm from the wall of the second channel portion 4304 in which the junction 4305 is formed in a direction along a line parallel to the main longitudinal axis of the second channel portion.
- This distance d2 is about 2.5mm (e.g. at least about 2.0mm, at least about 3.0mm, less than about 5.5mm, less than about 5.0mm).
- the distance between lower edge of slope 534 (proximal to junction 4305) at its most distal from the wall of the second channel portion 4302 in which the junction 4305 is formed, and in a direction along a line parallel to the main longitudinal axis of the second channel portion 4304, is called d3 and is about 0.5mm (e.g. at least about 0.4mm, at least about 1.0mm, less than about 2.0mm, less than about 1.8mm).
- the shortest distance from the upper edge of slope 534 to the lower edge of slope 534 is d4, which is about 2.0mm (e.g. at least about 1.5mm, at least about 2.5mm, less than about 3.0mm, less than about 3.5mm, less than about 4.0mm).
- the slope 534 has an angle of inclination ⁇ of about 8° (e.g. at least about 5°, less than about 15°, less than about 25°), being the angle of inclination of the slope 534 from the base of the second channel portion 4304 adjacent the junction 4305 and having height h3.
- Slope 534 and capillary stop 532 control movement of liquid through the second channel portion 4304 from liquid inlet 520 towards junction 4305.
- Liquid moving through the second channel portion 4304 from liquid inlet 520 towards junction 4305 has an advancing liquid meniscus forming a liquid:gas interface that is advancing towards junction 4305.
- capillary stop 532 Prior to reaching junction 4305 the advancing meniscus encounters capillary stop 532 which retards the movement of the advancing liquid meniscus along the inside wall 4307 of the bend portion.
- Capillary stop 532 thus acts to steer the liquid:gas interface around the corner in which capillary stop 532 is located, as described above.
- the advancing liquid:gas interface thus moves down chamfer 534 and across the face of the junction 4305 of the first and second channel portions.
- the bend portion, capillary stop 532 and slope 534 act together to advance the flow of liquid in the second channel portion 4304 towards the junction 4305 initially around the outside wall 4308 of the bend portion and past corner 536, thereby directing liquid flow across the wall in which the junction 4305 is formed. This acts to displace air from the liquid sample:air interface and form the liquid sample:liquid interface with minimum retention of air bubbles at the interface. Excess liquid flowing in the second channel moves into overflow channel 524 until it reaches vent 526.
- a liquid sample:liquid interface is thereby formed at the junction 4305 by flowing liquid in the second channel portion 4304 across a face of the liquid sample:air interface so as to displace the air from that interface and progressively decrease the area of the liquid sample:air interface until the air is displaced and the liquid sample:air interface is replaced by a liquid sample:liquid interface.
- liquid sample in the first channel portion is held substantially static. Once the liquid sample:liquid interface is formed and flow of liquid in the second channel part 4304 and overflow 524 has stopped the liquid sample:liquid interface is also substantially static with no bulk movement of liquid occurring across the interface, in either direction.
- the capillary stop formed at junction 4305 is designed to withstand normal capillary forces exerted by the sample fluid.
- the capillary stop can be breached if the force of the sample fluid flowing in the first channel portion is further increased, which may happen if excess sample is applied at the inlet or an external force is applied to the assay device.
- the liquid:liquid interface is stable and substantially static.
- the passive movement of particles across the interface e.g. from the liquid sample into the buffer liquid, should be kept to a minimum, e.g. in order to avoid unwanted cross-reaction of buffer substrate with components of the liquid sample and to minimise loss of magnetically susceptible particles from the liquid sample into overflow 524.
- the height (h' 1 ) of the first channel portion 4302 at the junction 4305 is less than the height (h 1 ) of the main body of the first channel portion 4302 (i.e. h 1 >h' 1 ).
- the base of the first channel portion 4302 includes a ramp extending upwards towards the junction 4305 (as shown in Figure 21), or alternatively (or additionally) extending downwards towards the junction 4305 from the lid of the first channel portion 4302.
- the ramp connects the parts of the first channel portion having heights h 1 and h' 1 .
- the first channel portion 4302 thus has restricted dimensions at the junction 4305 compared to the main body of the channel.
- the reduction in height of the first channel portion 4302 from h 1 to h' 1 has the effect of increasing the difference in height between the height of the first channel portion 4302 at junction 4305 (this being h' 1 ) and the height of the second channel portion 4304 at junction 4305 (h 2 ). This increases the capillary stop.
- one or more of the internal wall(s) (optionally including base and/or lid) of the first channel portion can be coated in a hydrophobic material at, and or proximal to, the junction 4305.
- This coating can be in the form of a hydrophobic patch, line or ring extending around the circumference of the first channel portion.
- the patch, line or ring can have a thickness of about 3mm (e.g. at least about 0.5mm, at least about 1mm, at least about 2mm, at least about 3mm, at least about 5mm).
- sample fluid deposited at inlet 510 can also be prevented or reduced by controlling the quantity of sample fluid deposited at the inlet 510.
- Sample fluid deposited at inlet 510 and in fluid connection with sample fluid in the first channel portion 4302 provides a head of pressure and the capillary stop pressure provided at junction 4305 is required to equal or exceed this in order to provide a stable liquid:air interface.
- deposit of an excess of sample fluid is prevented by partitioning the inlet into at least two compartments.
- One or more first compartments are in fluid connection with the first channel portion 4302 and, in combination with the first channel portion 4302, have a predetermined total volume (V i ) configured to provide a head of pressure that will not exceed the capillary stop pressure at junction 4305.
- V i is about 5 ⁇ l or about 10 ⁇ l (e.g. at least about 2 ⁇ l, at least about 5 ⁇ l, at least about 10 ⁇ l, less than about 30 ⁇ l, less than about 20 ⁇ l, less than about 15 ⁇ l). Excess sample fluid deposited at the inlet overflows from the first compartment(s) into one or more second compartments not fluidly connected to the first channel portion 4302.
- a filter is positioned at inlet 510 to prevent entry of red blood cells into first channel portion 4302 but allow entry of the fluid parts of the blood sample.
- a second liquid introduced to the second channel portion of assay device 500 to form the liquid sample:liquid interface is replaced by inclusion of a flowable media in the second channel portion.
- a liquid sample:flowable media interface is formed proximal the junction 4305. Magnetic transfer of magnetically susceptible particles across the interface into the flowable media and to the working electrode is then performed as described herein with respect to the other embodiments described.
- the assay device 500 does not require integration of reservoir 507.
- the flowable media can be a liquid.
- the flowable media is a viscous liquid or gel.
- the gel can be a matrix or electrophoresis gel such as an agarose or polyacrylamide gel, or other crosslinked polymer.
- the gel should provide a continuous flowable media path between the interface and sensor (e.g. working electrode 516w) allowing for movement of magnetically susceptible particle:first binding agent:analyte complexes from the interface through the gel to the sensor.
- the gel can also contain substrates (e.g. ABTS and H 2 O 2 ) required to detect analyte at the sensor.
- the first channel portion 4302 contains reagents.
- the reagents include multiple magnetically susceptible particles (e.g. at least about 50, at least about 100, at least about 150 magnetically susceptible particles) and a first binding agent configured to bind an analyte.
- the first binding agent is configured to also bind to the magnetically susceptible particles such that complexes of analyte:first binding agent:magnetically susceptible particle can be formed when the reagents are contacted with a liquid sample containing the analyte. These complexes can be magnetically moved through the liquid sample:liquid interface.
- the reagents include a second binding agent configured to bind the analyte at a different spatial location (epitope) on the analyte to the first binding agent.
- the first and second binding agents can both be bound to an analyte molecule at the same time to form a "sandwich" complex.
- the sandwich complex can comprise first and second binding agents bound to the analyte and magnetically susceptible particle bound to the first binding agent. These complexes can be magnetically moved through the liquid sample:liquid interface.
- the first or second binding agent can be conjugated to a detectable marker.
- the detectable marker can be any detectable label, e.g. enzyme label, fluorescent marker, radiolabel.
- An enzyme label can provide or cause a detectable signal, e.g. an electrochemical signal - oxidation or reduction at an electrode - following interaction with a substrate of the enzyme.
- a fluorescent marker can provide an optical signal - fluorescence - which can be detected by an optical sensor or scintillation counter.
- a radiolabel can provide an electromagnetic signal which can be detected by a sensor that can detect the electromagnetic radiation.
- the second binding agent is conjugated to an enzyme label, e.g. horse radish peroxidise.
- Second binding agent:enzyme label conjugates are further absorbed onto a colloidal sol particle, e.g. colloidal gold sol particles.
- the colloidal sol particles can have a diameter of about 20nm or about 40nm.
- the magnetically susceptible particles and first binding agent are modified to incorporate complementary linkers, e.g. one of biotin and streptavidin, in order to provide conjugates of the magnetically susceptible particles and first binding agent.
- the magnetically susceptible particles and first binding agent can be deposited in the first channel portion in pre-conjugated form, or can be deposited separately such that the conjugates form on mixing of the reagents in the liquid sample.
- a mixture of liquid/fluid reagents is introduced to the first channel portion 4302 and is then dried to provide a dry mixture reagent deposit.
- the analyte for detection in a blood sample contained in the first channel portion is NT-proBNP (e.g. human NT-proBNP).
- the first and second binding agents are anti-NT-proBNP antibodies that bind different epitopes on NT-proBNP.
- the first binding agent is:
- the first binding agent can be biotinylated to facilitate conjugation to streptavidin coated magnetically susceptible particles.
- the second binding agents can be conjugated to horse radish peroxidise and 20nm or 40nm diameter colloidal gold sol particles.
- NT-proBNP antibodies to NT-proBNP are publicly available, e.g. those available from HyTest Ltd., Intelligate 6th floor, Joukahaisenkatu 6, 20520, Turku Finland, e.g. monoclonal mouse anti-human NT-proBNP antibodies 5B6, 7B5, 13G12, 11D1, 16E6, 15D7, 24E11, 28F8, 18H5, 16F3 (Catalogue #:4NT1).
- Electrode 516w is positioned closest the junction 4305 at a distance of about 3.6mm to the centre line of the electrode from the junction (e.g. at least about 2mm, at least about 3mm, at least about 3.5mm, at least about 4mm, at least about 5mm, at least about 6mm, less than about 8mm, less than about 10mm).
- Electrode 516w has a width of about 2.4mm (e.g. at least about 2.0mm, at least about 2.5mm, less than about 3.5mm, less than about 3.0mm).
- the width of electrode 516w is sufficient to tolerate small variations in the positioning of magnetically susceptible particles and retain the ability to detect an electrochemical signal produced by reagent-substrate interaction at those particles.
- a counter electrode 516c Between the working electrode and reference electrode 516r is a counter electrode 516c.
- the working and counter electrodes are made from carbon paste and the reference electrode from silver paste.
- the reference electrode is an Ag/AgCl reference electrode and is about 1mm wide (e.g. at least about 0.6mm, at least about 0.8mm, less than about 2.0mm, less than about 1.4mm, less than about 1.2mm) and about 5mm from the centre line of the electrode from the junction 4305 (e.g. at least about 4mm, at least about 6mm, less than about 9mm, less than about 12mm).
- the enzyme label is horse radish peroxidase and the liquid in the second channel portion 4304 is a reaction buffer containing sodium acetate buffer, hydrogen peroxide substrate, and the redox mediator 2,2'-azino-bis-(3-ethylbenzo-thiazoline-sulfonic acid) (ABTS), as described above.
- the buffer liquid is 10mM ABTS, 10mM H 2 O 2 , 150mM KCl, 125mM sodium acetate; 0.1% v/v Tween-20TM , made to a final pH 4.2.
- the senor may comprise a region of the second channel portion at which a signal, e.g. fluorescence or colour, can be detected.
- the sensor can comprise a transparent portion of the device permitting interaction with a detector, e.g. a photodetector or scintillation counter, in meter 400.
- the device can have one or more "on-board controls" to serve as checkpoints for the proper operation of the device.
- a first on-board control can be the use of one of the electrodes 516w, 516c, 516r to detect flow of liquid from the liquid inlet 520 towards the junction 4305.
- Flow of liquid through the second channel portion 4304 will form a conductive bridge between two of the electrodes 516w, 516c, 516r.
- the meter 400 By operating meter 400 during liquid flow through the second channel portion 4304 towards the junction 4305 to detect current flow through two electrodes, e.g. the working and counter electrodes 516w and 516r, the meter can detect progress of the liquid towards the junction 4305.
- a second on-board control can be the use of an electrode or electrode pair 3601 positioned in overflow channel 524 to detect flow of liquid into the overflow channel and provide an indication of liquid sample:liquid interface formation at junction 4305.
- on-board controls can act as controls for the assay being performed.
- the enzyme label can be horse radish peroxidase, which catalyses conversion of hydrogen peroxide and ABTS to water and oxidised-ABTS. Hydrogen peroxide and ABTS are provided in the buffer liquid introduced to the second channel portion 4304.
- the presence and/or activity of the hydrogen peroxide and ABTS can be verified by immobilizing a predetermined quantity of the horse radish peroxidase enzyme label 5501 at electrode(s) 3601 in the overflow channel 524.
- Active buffer liquid components reaching the overflow will be catalysed and produce oxidized ABTS and an electrochemical signal that can be detected by electrode(s) 3601. Detection of a signal is indicative of active buffer components and serves to verify the validity of the determination made at working electrode 516w.
- the immobilized horse radish peroxidase can be substituted for an immobilized complex of magnetically susceptible particle:first binding agent:analyte:second binding agent, wherein the horse radish peroxidase is conjugated to the second binding agent.
- Such an arrangement may more accurately reflect the form of ternary complex formed at the working electrode 516w and provide an improved control.
- first and second electrodes (or pairs of electrodes) 5405, 5406 are provided in the overflow channel 524.
- a predetermined amount of horse radish peroxidase is immobilized 5401 at the first electrode pair 5405 and will produce a first electrochemical signal R 1 when buffer liquid containing hydrogen peroxide and ABTS is present.
- a second predetermined amount of horse radish peroxidase is immobilized 5402 at electrode pair 5406, wherein the second amount is larger than the first amount at electrode 5401.
- the second amount of horse radish peroxidase will produce an electrochemical signal R 2 when buffer liquid containing hydrogen peroxide and ABTS is present, where R 2 >R 1 .
- R 2 and R 1 can be configured to provide high and low control electrochemical signals, with respect to the selected assay and provide verification of the operable range of the assay.
- the immobilized horse radish peroxidase can be substituted for an immobilized complex of magnetically susceptible particle:first binding agent:analyte:second binding agent, wherein the horse radish peroxidase is conjugated to the second binding agent.
- Such an arrangement may more accurately reflect the form of ternary complex formed at the working electrode 516w and provide an improved control.
- on-board controls can be used to assess the state of the substrate(s) and/or reagent(s). For example, they can validate the activity of the substrate(s) and/or reagent(s) such that a valid assay result can be obtained. In another example, they can indicate that one or more of the substrate(s) and/or reagent(s) have lost or gained an activity or chemical state (e.g. oxidized/reduced), indicating that the assay result will not be valid within normal parameters and may need to be deemed void or be corrected.
- On-board controls of this kind can be performed independently of the presence of the sample, and provide information on the reagents and substrates used in the assay device.
- an on-board control that indicates the activity or viability of the reagent(s) and/or substrate(s) is provided.
- electrochemical detection of substrate and/or reagent activities is used to provide control values.
- dry reagent or substrate is used in the assay the on-board control will use a corresponding dry reagent or substrate, which may be re-hydrated prior to detecting the control signal.
- the on-board control for activity of the reagents comprises a predetermined quantity of reagent, e.g. enzyme reagent, deposited at or adjacent a defined location in the microfluidic network 508.
- this quantity of reagent is deposited at the same time as reagent is deposited in the reagent zone for interaction with the sample and is from the same batch of reagent.
- the reagent is deposited in the second channel portion 4304 at a location downstream of the junction 4305 with respect to the direction of flow of the second liquid, i.e. in the overflow 524.
- This reagent control is positioned in the overflow channel 524 such that reaction of the reagent and substrate does not affect or interfere with signal detection at the working electrode 516w which relies on the interaction of reagent bound to magnetically susceptible particles from the sample with substrate in the second liquid.
- a predetermined quantity of reagent is deposited in the overflow 524 at or adjacent a reagent control zone.
- the reagent control zone has one or more detection electrodes 3601, e.g. a set of three electrodes (working, counter and reference), to detect the reagent control signal.
- detection electrodes 3601 e.g. a set of three electrodes (working, counter and reference)
- substrate contained in the second liquid reacts with reagent at the reagent control zone to produce a signal that is detected by meter 400.
- the signal may be electrochemical or optical, for example.
- the reagent is horse radish peroxidase (HRP) and substrates are ABTS and H 2 O 2 .
- HRP horse radish peroxidase
- substrates are ABTS and H 2 O 2 .
- the reaction of HRP with ABTS and H 2 O 2 yields oxidized ABTS which can be electrochemically detected by the electrode set. Accordingly, the extent of oxidation of ABTS (and effectively loss of active (reduced) ABTS for conversion to oxidized ABTS by reaction with reagent) can be detected in the second liquid at the working electrode prior to interaction with reagent to provide a substrate control.
- a substrate control is also provided.
- the activity of the substrate may be determined at any chosen location in the second channel portion 4304 (or in a further channel portion provided for this purpose) provided that location is substantially free of reagent.
- the activity of the substrate is determined in the second liquid upstream of the junction 4305 and prior to transfer of magnetically susceptible particles across the junction 4305 into the second liquid.
- the substrate control signal indicates activity of the substrate in the absence of reagent.
- the substrate control signal is determined at electrodes 516w, 516r, 516c.
- the control signal values can be plotted against reagent concentration to provide a curve or line. Where more than one reagent control is provided the data from the additional reagent control(s), having different reagent concentrations, can also be used to plot the curve or line. This can be compared against a standard curve or line to determine the extent of deterioration of substrate or reagent activity and to calculate any adjustment that is required to be made to the assay result.
- the control signal detected is an electrochemical signal (e.g. ⁇ A).
- second liquid is forced from buffer pouch 507 into second channel portion 4304 such that the second liquid is directed towards junction 4305.
- the second liquid Prior to contact with the liquid:air interface, the second liquid contacts electrodes 516w, 516r and 516c and a substrate control signal is detected.
- Second liquid continues to flow towards junction 4305 to form the liquid sample:second liquid interface and second liquid flows into overflow 524 to contact the reagent control zone where the reagent control signal is detected.
- the substrate control and/or reagent control signals are processed by meter 400 to determine the activity of the substrate and/or reagent.
- the processing step can involve comparing the substrate control and/or reagent control signals against standard reference values for reagent and/or substrate activity, e.g. against an activity value for a laboratory standard.
- the determined control activity may be within a normal (expected) activity indicating that the assay may proceed and the assay result is valid.
- the determined control activities may be outside tolerated ranges (e.g. activity too low) and the assay result may be indicated as 'Void'.
- a modification or correction may be applied to the assay result to provide a valid assay result that is displayed to the user.
- the modification or correction assumes that the activity of all reagent and/or substrate contained in the assay device has deteriorated by the same amount or factor such that the assay result needs to be increased by a corresponding amount or factor.
- reagent activity is determined by detection of substrate activity, e.g. by detecting conversion of ABTS from reduced to oxidized form by the reagent.
- an on-board control for activity of substrate and reagent is provided by detecting the substrate activity (e.g. extent of oxidation of reduced ABTS substrate) at two positions in the second channel portion, each having different reagent concentrations.
- one of the reagent concentrations can be zero. To ensure substrate activity is measured at zero reagent concentration it can be detected at the working electrodes prior to movement of magnetic particles across the junction.
- the assay device provides for a stable, substantially static liquid sample:second liquid interface
- small quantities of liquid sample can be washed into the second liquid and into overflow 524.
- Reagent:magnetically susceptible particle complexes washed from the liquid sample into the second liquid will increase the quantity of reagent at the reagent control zone such that the reagent control signal detected is no longer a result only of interaction of the predetermined quantity of reagent deposited at the reagent control with the substrate but is affected by the presence of small quantities of additional reagent.
- the overflow channel is generally parallel to the first channel portion 4302 and is divided by a partition that is also substantially parallel to the first channel portion 4302 thereby forming a first overflow channel 2301 and a second overflow channel 2302.
- the first overflow channel 2301 provides an excess channel volume to receive second liquid, displacing air through vent 526 as the second liquid progresses along the first overflow channel 2301. This excess channel volume reduces the possibility of backflow of the second liquid.
- the second overflow channel 2302 is configured to receive at least some of the second liquid overflowing from the interface zone through an inlet. Distal to, and downstream of, the inlet the second overflow channel 2302 is tapered to form a narrow channel providing a vent 2303 through which air is dispelled as liquid fills the second overflow channel 2302. Vent 2303 is connected to the first overflow channel 2301. Vent 2303 is sufficiently narrow and hydrophobic that second liquid is substantially completely prevented from flowing through vent 2303 into the first overflow channel 2301. Accordingly, once filled the second overflow channel 2302 provides a defined volume of second liquid.
- the reagent control zone is positioned in the second channel portion in which detection of the reagent control signal takes place in a defined volume of second liquid. Any reagent particles washed into the overflow from the liquid sample:second liquid interface flow into the first overflow channel 2301 and do not interfere with detection of reagent activity in the reagent control zone. Where the second liquid contains a predetermined known quantity of substrate, the defined volume of second liquid in the second overflow channel 2302 can be used to determine the extent of reaction of substrate and reagent and the activity of substrate and/or reagent.
- a single overflow channel is provided.
- the reagent control zone is positioned sufficiently far away from the interface zone that any particles washed into the second liquid overflow settle out in the overflow channel prior to reaching the reagent control zone such that detection of the reagent control signal takes place in second liquid that is free or substantially completely free of reagent.
- the overflow channel 524 has a length in the region of at least about 2 times the length of the second channel portion 4304 (e.g. at least about 2.5 times, at least about 3 times, at least about 4 times).
- the overflow channel defines a flow path initially substantially parallel to the flow path defined by the first channel portion, but thereafter may take any desired flow path to provide the required length of channel.
- the overflow channel may include one or more bend portions changing the direction of the flow path defined by the channel.
- the reagent control zone is located in the overflow channel 524 at least about 20mm (e.g. at least about 30mm, at least about 40mm, at least about 50mm, at least about 60mm, at least about 70mm, at least about 80mm, at least about 90mm, at least about 100mm) downstream of junction 4305.
- the reagent control zone is located downstream of a first bend portion in the overflow channel (not including any bend portion at the connection between the second channel portion and the overflow 524 immediately downstream of the junction 4305).
- meter 400 accepts test assay device 500 and includes display 406.
- the display 406 may be used to display images in various formats,. Display 406 can also be used to display information to patients.
- Display 406 can provide a user with an input region 404.
- Input region 404 can include keys.
- User instructions and queries are presented to the user on display 406. The user can respond to the queries via the input region.
- Meter 400 also includes an assay device reader, which accepts diagnostic test assay devices 500 for reading.
- the assay device reader can measure the level of an analyte based on, for example, the magnitude of an optical change, an electrical change, or other detectable change that occurs on a test assay device 500.
- the assay device reader can include electrical systems for measuring the detectable change, including, for example, a voltameter or amperometer.
- meter 400 is shown along with assay device 500.
- Meter 400 has a port 402 that receives assay device 500.
- a user of meter 400 inserts an assay device 500 through port 402 prior to performing an analysis of a sample.
- Meter 400 is configured to operate assay device 500 when assay device 500 has been inserted through port 402.
- Meter 400 includes a liquid reservoir actuator, a magnetic actuator, electrochemical detector, and a processor.
- Reservoir actuator is configured to actuate reservoir 507 of device 500.
- the magnetic actuator is configured to manipulate (e.g., move and/or position) magnetically susceptible particles within microfluidic network 508 of assay device 500.
- the electrochemical detector is configured to determine the presence of analyte transported to electrodes 516w, 516r, 516c by the magnetically susceptible particles.
- the electrochemical detector includes electrical contacts which respectively communicate with electrical contacts 518w, 518r, 518c of device 500 when received within meter 400.
- assay device 500 is inserted into meter 400 via port 402.
- a sample e.g. a blood sample
- An amount of the sample (e.g., at least about 5 ⁇ l or 10 ⁇ l) moves into microfluidic network 508 (e.g. by capillary action).
- the sample interacts with reagents in the reagent zone.
- Target analyte is then transported to the detection zone where an electrochemical signal is recorded.
- Target analyte interacts with electrodes 516w, 516r, 516c and a signal is detected by the electrochemical detector.
- the processor interprets the signal detected by the electrochemical detector and displays information to a user on interface 406.
- the analyte is N terminal pro-brain natriuretic peptide (NT-proBNP) and the sample material is whole blood from a human.
- NT-proBNP N terminal pro-brain natriuretic peptide
- the presence of NT-proBNP is indicative of a cardiac condition (i.e., a physiological condition related to the heart (e.g., a cardiac dysfunction such as heart failure)).
- a cardiac condition i.e., a physiological condition related to the heart (e.g., a cardiac dysfunction such as heart failure)
- the presence of the cardiac condition can be determined. For example, it can be determined whether the human has experienced, is experiencing, or has a tendency to develop heart failure.
- the reagents include the following species; a first antibody capable of binding to NT-proBNP, a second antibody capable of binding to NT-proBNP concurrently with the first antibody, an anti-coagulant to prevent clotting of the blood sample within the reagent zone, at least one magnetic particle, an enzyme label that can be used to produce a detectable species, buffer salts, and at least one colloidal particle.
- the first antibody can be modified with biotin
- the second antibody can be conjugated with the enzyme label.
- the second antibody-enzyme conjugate can be adsorbed onto a colloidal gold sol particle to increase the number of antibody-enzyme conjugates.
- the magnetic particle can be coated with streptavidin, which can be used to capture the biotin modified first antibody.
- the streptavidin coated magnetic particle can accommodate a number of biotin modified antibodies.
- the biotin modified first antibody binds to a first unique region of NT-proBNP.
- the second antibody-enzyme conjugate binds to a second unique region of NT-proBNP.
- Second antibody-enzyme conjugate is provided pre-associated with gold sol particles thus increasing the number of enzyme labels that become part of the NT-proBNP antibody complex.
- a first monoclonal antibody, clone 15F11 was biotin modified
- a second antibody, clone 24E11 was conjugated with HRP.
- Example 1 Detection of NT-proBNP in a human blood sample
- a human blood sample is added to the assay device 500 at inlet 510.
- the blood contains an amount of an analyte: N-terminal truncated pro-brain natriuretic peptide (NT-proBNP).
- the sample of blood enters the first channel portion 4302, e.g. via capillary action, where it mixes with reagents in the reagent zone.
- the reagents in the reagent zone include streptavidin coated magnetically susceptible particles and biotinylated first binding agent which is an anti-NT-proBNP antibody 15C4 (HyTest Ltd.; Catalogue #:4NT) and horseradish peroxidase ("HRP") conjugated to a second binding agent which is anti-NT-proBNP antibody 15F11 or 29D12 (HyTest Ltd.; Catalogue #:4NT) (the antibody-linked enzyme).
- the assay device and included reagents are provided in a dry state. Addition of a liquid sample to the assay device (i.e., to the inlet and first channel portion) re-suspends dry reagents.
- the reagents are re-suspended in solution with the blood, and form a mixture.
- the streptavidin coated magnetically susceptible particles bind to the biotinylated first binding agent to form a conjugate (the antibody-linked magnetically susceptible particle).
- the NT-proBNP in the blood is also bound by the first binding agent and a ternary complex of NT-proBNP bound antibody-linked magnetically susceptible particle is formed.
- a magnetic field is applied such that the magnetically susceptible particles undergo an induced motion (e.g., a periodic or oscillatory motion) to promote resuspension and mixing of the reagents with the sample.
- the blood sample fills the first channel portion 4302 and on reaching junction 4305, the liquid forms a meniscus.
- the change in cross-sectional area of the channel at junction 4305 does not allow the blood sample to fill the second channel portion 4304. Rather, capillary pressure in the second channel portion exceeds any capillary forces that draw the sample liquid beyond junction 4305 into the second channel portion 4304.
- Junction 4305 thus acts as a capillary stop, preventing substantial liquid sample flow beyond that point.
- a blood sample:air interface is formed by the blood meniscus at junction 4305.
- a magnetic field is applied to the first channel portion 4302.
- the applied field is manipulated so as to move the magnetically susceptible particles, and all components bound to them.
- the magnetically susceptible particles are magnetically moved along the first channel portion 4302 toward junction 4305.
- a buffer liquid is added to the device at the second inlet 520.
- a buffer pouch 507 incorporated into the device delivers the reaction buffer.
- the buffer liquid contains 10mM of the redox mediator 2,2'-azino-bis-(3-ethylbenzo-thiazoline-sulfonic acid) (ABTS), 10mM H 2 O 2 , 150mM KCl, 125mM sodium acetate; 0.1% v/v Tween20, made to a final pH 4.2.
- the buffer does not contain analyte (NT-proBNP).
- the buffer liquid flows along the second channel portion 4304 to junction 4305, where the buffer liquid contacts the blood sample at the blood:air interface to form a blood:buffer interface.
- the magnetically susceptible particles (and all that is bound to them) are moved across the blood:buffer interface by moving the applied magnetic field across the junction 4305 into the second channel portion 4304 and towards the working electrode 516w.
- the formation of the blood:buffer interface facilitates the magnetic movement of the magnetically susceptible particles (and all that is bound to them) from the blood to the buffer, leaving interfering sample components and analytes that are not of interest in the blood in the first channel portion 4302.
- the magnetically susceptible particles and all that is bound to them, including the NT-proBNP in the form of a ternary complex of NT-proBNP with antibody-linked magnetically susceptible particle and antibody-linked enzyme
- the magnetically susceptible particles bound to NT-proBNP are next moved to the working electrode 516w by manipulation of the applied magnetic field.
- the magnetically susceptible particles are magnetically positioned and held at the detection zone for an incubation time of e.g. 1 minute.
- Magnetically susceptible particles bound to NT-proBNP and the second binding agent:HRP conjugates are detected electrochemically by HRP mediated catalysis of hydrogen peroxide and ABTS to water and oxidised-ABTS.
- the electrochemical current produced by the reduction of oxidized ABTS at the electrodes is measured at the working electrode for a measurement period (e.g. 3 seconds).
- the detected electrochemical current is received in meter 400 and compared against a corresponding calibration dataset to determine an amount and/or concentration of NT-proBNP.
- the meter displays or communicates an assay result to the user.
- Electrochemical measurements can be made using a single time point of HRP turnover time.
- a typical dose response curve for concentrations of 0-20,000 pg/ml NT-proBNP in the liquid sample is shown in Figure 17 .
- the performance of the electrochemical NT-proBNP assay may be optimised by extending the measurable range and linearising the response at the higher NT-proBNP concentrations. To achieve this we identified whether the plateau effect was a reagent, electrochemical or combined reagent and electrochemical limitation.
- the ability to measure the HRP concentration electrochemically via the mediator ABTS provides the flexibility to tune the immunoassay response.
- captured HRP was allowed to react for a 1 minute turnover period (incubation time). No potential was applied to the electrode until after the 1 minute HRP turnover period, the subsequent potential applied was used to reduce the oxidised ABTS generated by the HRP.
- HRP titrations were performed to investigate the HRP turnover time on the sensitivity, linearity and range of the response.
- the HRP was homogeneously distributed within the channel and not concentrated in the vicinity of the electrode when placed on the electrode via the magnetic particles.
- the linear range of the HRP is seen to vary with turnover time.
- a 10 minute turnover time results in an approximately linear range up to 5000 pM HRP; a 1 minute turnover time results in an approximately linear range up to 20,000 pM HRP; a 30 second turnover time results in a approximately linear range of 50,000 pM HRP; a 15 second turnover time results in an approximately linear range of 80,000 pM HRP.
- NT-proBNP concentrations it is desirable to be able to measure NT-proBNP concentrations over a 50-20,000 pg/ml range. This is a dynamic range for an immunoassay to measure. It would also be desirable to distinguish a doubling in NT-proBNP concentration. It would also be desirable to linearise the electrochemical response over the higher NT-proBNP concentrations.
- a 15 second turnover time allows the measurement of up 40,000 pg/ml NT-proBNP and easily allows the ability to measure the doubling of 5000 to 10000 to 20000 to 40000 pg/ml. This result demonstrates how the assay can be tuned for optimum performance.
- a two point electrochemical measurement can be made to measure the desired range with optimum performance, for example a 15 second measurement to capture the high NT-proBNP concentrations as shown and then a second measurement (e.g. 1, 2, 3 minutes) to measure the low NT-proBNP concentrations resulting in 2 calibrations curves for maximum sensitivity and performance.
Description
- The present invention relates to assays.
- Heart failure is a chronic, progressive disease that affects a substantial portion of the world's population. The prevalence and incidence of heart failure is growing due to an aging population and a greater number patients who survive a myocardial infarction.
- Clinically, heart failure can be characterized by a syndrome of breathlessness and fatigue, often accompanied by fluid retention, as indicated by an elevated jugular venous pressure and edema. The progression of heart failure is defined in four stages. The term heart failure refers to all of these. Stage A-at risk: patients at high-risk of developing heart failure (patients with coronary heart disease, diabetes, hypertension, and/or valvular heart disease). Stage B-pre-heart failure: patients with structural heart disease but without clinical heart failure symptoms, many of whom have decreased systolic function. Stage C-heart failure: patients who have prior or current symptomatic heart failure due to systolic or diastolic dysfunction and who are responding to therapy. Stage D-advanced heart failure: patients in end-stage or refractory-to-therapy.
- Many of the tests and procedures for accurately and successfully diagnosing, managing and treating heart failure are complex, expensive and available only at a hospital or other health-care setting.
-
WO 2007/002579 relates to devices and methods for performing a test to detect and/or quentify the presence of an analyte of interest within a sample using a portable instrument. -
US 5,279,936 relates to methods for separating a component of interest from a mixture containing the component of interest and other components. -
WO 2007/110779 relates to an essay method and device that can perform at least one assay on a single aliquot of a sample liquid. The device can mix the sample liquid with assay reagents including magnetically susceptible particles.
WO 2007/110739 relates to a method and apparatus for processing of particles in which the particles suspended in a first fluid are introduced under laminar flow conditions into at least one first micro chamber of first region of the same, in which a second fluid is introduced under laminar flow conditions into at least one second region of the micro chamber or a second micro chamber in such a way as not to mix with the first fluid. - The present invention relates to assays.
- Also disclosed is a method comprising: (a) introducing a liquid sample to a first portion of a channel of a micro fluidic device; (b) contacting, within the microfluidic device, reagent with the liquid sample; (c) contacting, within the microfluidic device, liquid sample with a second liquid wherein the second liquid contains substrate of the reagent; (d) detecting a characteristic of the substrate in the second liquid at a first position in the microfluidic device; (e) contacting the second liquid with reagent at a second position in the microfluidic device and detecting a characteristic of the contacted substrate and/or reagent; (f) contacting reagent from said liquid sample with substrate in the second liquid and detecting a characteristic of the contacted liquid sample reagent and/or substrate; (g) using the characteristics detected in (d) and (e) to validate or adjust the characteristic detected in (f).
- In one instance detection of a characteristic of the substrate at the first position is in the absence of reagent, i.e. reagent concentration is zero. Preferably, therefore, the second liquid has not contacted reagent.
- In other instances detection of a characteristic of the substrate at the first position is where the second liquid has contacted a first concentration of reagent. Thus, step (d) can comprise contacting the second liquid with a first concentration of reagent and detecting a characteristic of the contacted substrate and/or reagent at the first position. At the second position substrate in the second liquid can contact a second concentration of reagent wherein the second concentration of reagent is different to the first concentration of reagent.
- In some instances contacting of the liquid sample with second liquid comprises forming, proximal to a junction between the first portion of the channel and a second portion of the channel, a liquid sample:gas interface; and forming a liquid sample:second liquid interface by flowing a second liquid toward said junction and displacing gas of the liquid sample:gas interface with a second liquid.
- In some instances detecting a characteristic of the substrate in (d) occurs in the second liquid. Detecting a characteristic of the substrate in (d) can take place prior to formation of the liquid sample:second liquid interface. Detecting a characteristic of the substrate in (d) can occur at a location upstream of said junction with respect to the direction of flow of said second liquid.
- In some instances detecting a characteristic of the substrate and/or reagent in (e) occurs in the second liquid. Detecting a characteristic of the substrate and/or reagent in (e) can take place after formation of the liquid sample:second liquid interface. Detecting a characteristic of the substrate and/or reagent in (e) can occur at a location downstream of said junction with respect to the direction of flow of said second liquid.
- In some instances detection of the characteristic of the contacted liquid sample reagent and/or substrate in (f) occurs in the second liquid. Detection of the characteristic of the contacted liquid sample reagent and/or substrate in (f) can take place after formation of the liquid sample:second liquid interface. Detection of the characteristic of the contacted liquid sample reagent and/or substrate in (f) can occur at a location upstream of said junction with respect to the direction of flow of the second liquid. The detection of this characteristic can involve the detection of an assay result at a detection zone in the second channel portion of the microfluidic device.
- In some instances, the first and second position are in a second channel portion of the microfluidic device, wherein the first position is in a detection zone for detecting an assay result and the second position is in an overflow channel, e.g. at a reagent control zone. The first and second positions are spatially separated in the channel network of the microfluidic device such that following contact with the second liquid mixing, between respective positions, of reagents deposited at or near the respective positions does not occur or is negligible. Reagent can be deposited at the first and/or second positions, or adjacent or proximal to the respective position(s). Detection of the characteristic can occur close to the location of deposited reagent and can be at, adjacent or proximal to, the first and second positions. Sensors can be positioned at the respective positions to detect the characteristic.
- Also disclosed is a method further comprising the step of comparing a detected characteristic against a reference value. A reference value can be a laboratory standard. It can represent a known activity of the substrate or reagent prior to incorporation in the microfluidic device such that a change in the activity of the substrate or reagent following storage in the microfluidic device can be determined. The comparison step can therefore provide a control for changes in substrate and/or reagent activity.
- The detected characteristics of the substrate and reagent at the first and second positions can be used as controls for reagent and/or substrate activity, which are useful to determine whether reagents used in the assay have undergone a change in activity (e.g. reduction in activity) which may affect the assay result. The control values detected can be used to validate the assay result or adjust the assay result to take account of a change in reagent or substrate activity.
- Therefore the method can comprise using the detected characteristics from (d) and (e) to determine a difference in activity of substrate and/or reagent contained in the microfluidic device from a respective reference activity or activities. Determining the difference can involve calculating a difference in activity of substrate and/or reagent contained in the microfluidic device from a respective reference activity or activities. This difference can be used to validate the detected characteristic of the contacted liquid sample reagent and/or substrate, e.g. the assay result. This difference can also be used to adjust a detected characteristic of the contacted liquid sample reagent and/or substrate, e.g. to calculate and apply a correction to the characteristic of the contacted liquid sample reagent and/or substrate. Thus, in some disclosed methods the initial assay result is corrected to provide an adjusted final assay result.
- The step of contacting, within the microfluidic device, reagent with the liquid sample comprises contacting, in the first portion of the channel, reagent and magnetically susceptible particles with the liquid sample, the magnetically susceptible particles forming a complex with the reagent and comprising a binding agent configured to bind an analyte in the liquid sample. The method may further comprise the step of magnetically moving magnetically susceptible particle .reagent complexes across the liquid sample:second liquid interface into the second liquid and to a detection zone in the second channel portion.
- The reagent can be, or comprise, one or more enzymes. In some embodiments the reagent is horse radish peroxidase and the substrate is ABTS. The second liquid can also contain hydrogen peroxide.
- Also disclosed is a method comprising: (a) mobilizing, within a microfluidic device and using a liquid sample, a dry reagent, the liquid sample containing an analyte, (b) subsequently forming, within the microfluidic device, a second liquid-liquid sample interface between a second liquid and the liquid sample, the second liquid comprising a second reagent which is a substrate of the dry reagent; (c) subsequently detecting, at a first position within the microfluidic device, a characteristic of a first amount of the substrate in the second liquid; (d) moving an amount of the mobilized dry reagent and the analyte from the liquid sample into the second liquid to a second position within the microfluidic device, the amount of moved mobilized dry reagent being indicative of the amount of analyte present in the liquid sample; (e) detecting a characteristic of the substrate at the second position; (f) using the characteristics detected in (c) and (e) to validate or adjust the characteristic detected in (e), the validated or adjusted characteristic being indicative of the amount of mobilized dry reagent moved to the second position.
- In some instances the first amount of substrate is the amount or portion of substrate contained in the second liquid in the region of the reagent control zone and from which the characteristic is detected. The characteristic of the first amount of the substrate can be independent of the amount of analyte present in the liquid sample.
- Detection of a characteristic can comprise determination of a characteristic. This may comprise determining, measuring or detecting a signal (quantitatively or qualitatively). The detection can be determining the conversion of one or more substrates into one or more products. In some embodiments detecting a characteristic of the substrate comprises electrochemical detection of oxidized or reduced substrate. This can comprise detection of the oxidation or reduction state of the substrate. In other embodiments it can comprise detection of a fluorescent marker or label.
- In one aspect, a method includes transporting a magnetic or magnetically susceptible particle across an interface between a sample reagent mixture and another medium (e.g., a fluid such as a gas or liquid). The particle includes a binder for an analyte or analyte complex. The analyte is determined after transporting the particle and bound analyte across the interface. At least the step of transporting can be performed in a microfluidic device.
- The method may include introducing a liquid sample to a first portion of a channel of a microfluidic device; contacting, within the microfluidic device, magnetically susceptible particles with the liquid sample, the magnetically susceptible particles comprising a binding agent configured to bind an analyte; forming, proximal to a junction between the first portion of the channel and a second portion of the channel, a liquid sample:gas interface; forming a liquid sample:second liquid interface by displacing gas of the liquid sample:gas interface with a second liquid, and magnetically moving the magnetically susceptible particles across the liquid sample:second liquid interface into the second liquid.
- The method may be a method for detecting an analyte in the liquid sample, the magnetically susceptible particles adapted to bind the analyte wherein the method further comprises the step of detecting analyte in the second liquid.
- The method may be for detecting an analyte and comprise the step of determining an amount of the analyte.
- The method may include separating an analyte from the liquid sample and transporting the analyte into the second liquid.
- The method may be an in vitro method.
- The first and second liquids are typically different. The first liquid may be a bodily fluid from a human or mammal (e.g., blood, serum, or plasma). The second liquid may be a buffer solution.
- The method may be an in vitro method for detecting an analyte in a liquid sample of blood, plasma or serum from a human comprising introducing the liquid sample to a first portion of a channel of a microfluidic device; contacting, within the microfluidic device, magnetically susceptible particles with the liquid sample, the magnetically susceptible particles comprising a binding agent configured to bind an analyte; forming, proximal to a junction between the first portion of the channel and a second portion of the channel, a liquid sample:gas interface; forming a liquid sample:second liquid interface by displacing gas of the liquid sample:gas interface with a second liquid, and magnetically moving the magnetically susceptible particles across the liquid sample:second liquid interface into the second liquid.
- The method may include determining an assay result. The method may include determining an amount of the analyte. The method may include comparing the amount of analyte determined against a reference amount to produce an assay result. The method may include displaying the determined amount of analyte. The method may include displaying information based on an assay result. The information may be indicative of the assay result (e.g., may be indicative of the amount of analyte in the second liquid). The assay result displayed may be proportional to the amount of analyte in the second liquid.
- Forming a liquid sample:second liquid interface by displacing gas of the liquid sample:gas interface with a second liquid may comprise directing the second liquid across the face of the liquid sample at the liquid sample:gas interface.
- Forming a liquid sample:second liquid interface by displacing gas of the liquid sample:gas interface with a second liquid may comprise directing a flow of second liquid across the face of the liquid sample at the liquid sample:gas interface to decrease an area of the liquid sample:gas interface. During flow of the second liquid across the face of the liquid sample the first liquid may be held essentially static.
- The method may comprise the step of forming a liquid sample .second liquid interface in which substantially no bulk movement of liquid (other than diffusion) occurs across the interface.
- The method may comprise the step of magnetically positioning magnetically susceptible particles at a predetermined detection zone in the second channel portion.
- The method may comprise magnetically moving the magnetically susceptible particles adjacent or upon a sensor located in, or juxtaposed to, the second channel portion of the device. The particles may be magnetically retained adjacent or upon the sensor for an amount of time sufficient for the sensor to detect a characteristic of the second liquid.
- The method may include magnetically positioning the magnetically susceptible particles adjacent one or more electrodes configured in the second channel portion to contact the second liquid. The method may include detecting a characteristic of the second liquid at the electrode(s). The step of detecting a characteristic may comprise detecting an electrochemical signal in the second liquid. The magnetically susceptible particles may be held adjacent or upon the one or more electrodes for an amount of time sufficient for the electrodes to detect an electrochemical signal in the second liquid. The detection may comprise detecting the presence of analyte in the second liquid. The detection may comprise detecting an amount of analyte in the second liquid.
- The step of introducing the liquid sample may comprise depositing a quantity of the liquid sample at an inlet of the device, wherein the inlet is in fluid connection with the first channel portion.
- The method may be a diagnostic method.
- The method may be performed outside of the presence of a medical practitioner. In some embodiments, the method is a method for detecting NTproBNP in a liquid sample of blood, plasma or serum from a human and the method includes introducing the liquid sample to a first portion of a channel of a microfluidic device; contacting, within the microfluidic device, the liquid sample with reagents comprising magnetically susceptible particles conjugated to a first anti-NTproBNP antibody, and a second anti-NTproBNP antibody conjugated to an enzyme label, to form complexes comprising magnetically susceptible particle, NTproBNP and enzyme label; forming, proximal to a junction between the first portion of the channel and a second portion of the channel, a liquid sample:gas interface; forming a liquid sample:second liquid interface by displacing gas of the liquid sample:gas interface with a second liquid; magnetically moving the magnetically susceptible particles across the liquid sample:second liquid interface into the second liquid; and detecting NTproBNP in the second liquid.
- The liquid sample:gas interface may be essentially static with respect to movement along the channel between forming the liquid sample:gas interface and forming the liquid sample:second liquid interface.
- The invention relates to a device as set out in
independent claim 1. - In some embodiments proximal to the junction one or more of the internal wall(s) of the first channel portion are hydrophobic. Proximal to the junction one or more of the internal wall(s) of the first channel portion can have a hydrophobic patch, a hydrophobic line or a hydrophobic ring extending around the circumference of the first channel portion.
- In some embodiments the inlet is partitioned into one or more first compartments in fluid connection with the first channel portion thereby defining a total volume of the first channel portion and first compartments (Vi), and one or more second compartments not in fluid connection with the first channel portion.
- In some embodiments the second channel portion has a liquid overflow channel portion, said overflow channel portion partitioned into a first overflow channel portion proximal the junction and a second overflow channel portion distal to the junction, wherein the reagent control zone is located in the second overflow channel portion. The main longitudinal axis of at least one of the first and second overflow portions can be substantially parallel to the first channel portion.
- Also described is a device that comprises:
- an inlet in fluid connection with a first portion of a channel, the inlet configured to receive a liquid;
- a second portion of the channel connected to the first portion at a junction;
- magnetically susceptible particles disposed in the first channel portion;
- wherein the device is configured to form, with a liquid received by the inlet, a liquid interface proximal the junction,
- the device further comprising:
- a reservoir containing a quantity of second liquid and configured to deliver second liquid released from the reservoir into the second channel portion such that the second liquid flows towards the junction, and
- at least one sensor configured on the second channel portion to detect a signal from the second liquid,
- wherein the second channel portion has a liquid overflow channel portion, said overflow channel portion partitioned into a first overflow channel portion proximal the junction and a second overflow channel portion distal to the junction, wherein the reagent control zone is located in the second overflow channel portion.
- In some embodiments the main longitudinal axis of at least one of the first and second overflow portions can be substantially parallel to the first channel portion.
- The first portion of the channel has a main channel height h1 and a
channel height h'1 at the junction, wherein h1>h'1 and wherein at the junction, the first channel portion has height h'1 and the second channel portion has height h2, wherein h2>h1>h'1. Proximal to the junction one or more of the internal wall(s) of the first channel portion can be hydrophobic. - The assay method and device can be used in home testing kits for analyzing species present in the blood. In particular, the device and method facilitate the performance of more than one assay on a small sample volume, and are suitable for use with home testing kits that use the "finger stick" or "finger prick" procedure.
- The assay device and method can accept small fluid samples in a simple step, and is able to present small fluid samples for immediate testing in a reliable and reproducible fashion. The present invention provides an efficient way to utilise obtained blood samples in a home testing kit by allowing the performance of a series of tests on the same sample. Finally, the device and method facilitate the execution of more than one assay on the same blood sample by separating and isolating analytes of interest, within a complex mixture. This enables the visualisation of the analytes by a detection procedure. In particular, the present invention affords the use a specific reagent for visualising a marker related to an analyte and the reliable quantification of its presence to inform on a disease state in a subject.
- Embodiments permit determination of one or several analytes, such as analytes indicative of disease states in a subject, to be detected.
- The invention includes the combination of the described aspects and features except where such a combination is clearly impermissible or expressly excluded.
-
-
Figure 1 is a flow chart of an assay method; -
Figure 2 is perspective view of an assay device and meter suitable for performing the assay method; -
Figure 3 shows a perspective view of an assay device (including buffer pouch); -
Figure 4 shows a plan view of an assay device above (excluding buffer pouch); -
Figure 5 shows a perspective view of an assay device from underneath; -
Figure 6 shows a perspective view from above of the component layers of an assay device; -
Figure 7 shows a plan view of an exemplary embodiment of an assay device from above, including component dimensions (mm); -
Figure 8 shows an enlarged view of the interface zone Z fromFigure 7 ;Figure 9 shows a plan view of the upper part of an assay device (excluding buffer pouch); -
Figure 10A shows a cross-section through the assay device along line B-B, shown inFigure 10B ;Figure 10C shows an enlarged view of detail W fromFigure 10A ;Figure 10D shows an enlarged view of detail U fromFigure 10A ;Figure 1 IA shows a cross-section through the assay device along line C-C, shown in
Figure 1 IB; -
Figure 11C shows an enlarged view of detail V fromFigure 1 IA; -
Figures 12A and12B show plan views of the microfluidic network of one exemplary embodiment of the assay device (dimensions inFigure 12B in mm); -
Figure 13 shows an enlarged view of the interface of the buffer pouch and sharp projection; -
Figure 14 shows an enlarged view of the junction in one exemplary embodiment of the assay device; -
Figures 15A-B show on-board control configurations;Figures 16A-D show on-board control configurations;Figure 17 shows a typical dose response curve for NT-proBNP concentrations 0-20,000 pg/ml; -
Figure 18 illustrates summary HRP titration data at turnover times of 10 mins, 1 min, 30 sec and 15 seconds; -
Figure 19 illustrates NT-proBNP electrochemical assay results for 0, 5000, 10,000, 20,000 and 40,000 pg/ml NT-proBNP with HRP turnover times of 1 min, 30, 15 and 5 seconds; -
Figure 20 illustrates a semi-log plot of NT-proBNP electrochemical assay results at a 15 sec turnover time. - Assays for determining (e.g. quantitatively or qualitatively) one or more analytes or indicators in sample material (e.g., a biological sample) are described. Typical analytes are biomarkers related to (e.g., indicative of) the presence of a physiological condition in a mammalian subject. The presence of the physiological condition can be determined based at least in part on the result of the determination of the biomarker (e.g., by comparing the result to a reference value).
- The assays can be for use in reaching a diagnosis or prognosis. Assay methods can comprise methods of diagnosis or prognosis of a pathological condition or disease state in a user or susceptibility of the user to a pathological condition or disease state. The assay device can be provided for use in a method of diagnosis or prognosis of a pathological condition or disease state in a user or susceptibility of a user to a pathological condition or disease state. In exemplary embodiments the assay method is an in vitro method not practised on the human or animal body. In exemplary embodiments the assay method is practised on a liquid sample which may be a sample collected from the human or animal body, e.g. a bodily fluid sample such as a human blood sample. In exemplary embodiments the sample is used to conduct the assay and is then discarded, and is not returned to the human or animal from which it was collected.
- In exemplary embodiments, magnetically susceptible particles are used in the capture of an analyte, the separation of an analyte from a liquid sample, and in the positioning of the analyte proximal a detection zone.
- In some embodiments, an analyte is separated from a liquid sample. After being separated, the analyte is detected in a second medium (e.g., another fluid (e.g., a gas such as air, a different liquid such as a buffer) or flowable medium (e.g., a gel, such as an electrophoresis gel). An exemplary method includes combining magnetically susceptible particles adapted to bind the analyte with the liquid sample to form complexes of magnetically susceptible particle bound analyte. The complexes are magnetically separated from the liquid sample into the second medium.
- Separation of the complexes from the liquid sample into the second medium (e.g., another fluid (e.g., a gas such as air, a different liquid such as a buffer) or flowable medium (e.g., a gel, such as an electrophoresis gel)) is typically achieved by a method that includes forming an interface between the liquid sample and second medium. In embodiments, the interface is stable, and essentially static (i.e. diffusion may occur with respect to the interface but the position of the interface is essentially constant). For example, in embodiments in which the interface is performed within a microfluidic device, the position of the interface relative to the microfluidic device may be essentially constant (e.g., the relative position may change by about 5 mm or less, about 2.5 mm or less, about 1 mm or less) at least prior to the transport of the magnetically susceptible particles across the interface as described below. Typically, bulk movement of at least one (e.g., both) of the liquid sample and second medium does not occur with respect to the interface at least prior to the transport of the particles across the interface. In an exemplary embodiment, the position of the interface is essentially constant at least prior to determination of the analyte.
- The interface is typically substantially free of gas bubbles. For example, it can be free of gas bubbles or may contain a small number of gas bubbles that do not prevent transfer across the interface of substantially all of the magnetically susceptible particles clustered in the liquid sample adjacent the interface, wherein substantially all of the magnetically susceptible particles is at least about 70% (e.g. at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%) of the clustered magnetically susceptible particles.
- In exemplary embodiments, the interface is formed between the liquid sample and the second medium (e.g., another fluid (e.g., a gas such as air, a different liquid such as a buffer) or flowable medium (e.g., a gel, such as an electrophoresis gel)). In exemplary embodiments the interface is defined by the contacting parts of the liquid sample and the second medium.
- A magnetic field is applied to the magnetically susceptible particle:analyte complexes in the liquid sample and the complexes are magnetically moved towards the liquid sample:second medium interface. The magnetic field moves the complexes across the interface and into the second medium. The transport across the interface separates the complexes from the liquid sample.
- In exemplary embodiments movement of substantially all of the magnetically susceptible particle:analyte complexes across the liquid sample:liquid interface is optimized by controlling the speed of movement of the magnetic field towards the interface, and across the interface. The timing of movement of the magnetically susceptible particle:analyte complexes across the interface can be controlled to be coincident with, or very shortly after, formation of the liquid sample:second liquid interface.
- Having separated the complexes from the liquid sample, the complexes can be further magnetically moved to a sensor (e.g., an electrochemical sensor including one or more electrodes), where the presence of analyte can be detected directly or indirectly.
- In exemplary embodiments an indirect detection is performed wherein the complexes include an enzyme label capable of producing a detectable reaction in the presence of one or more enzyme substrates and/or cofactors. For example, the enzyme may produce a product such as an oxidized or reduced enzyme substrate, cofactor or byproduct. The product can be detected electrochemically using the electrochemical sensor. For example, the electrochemical sensor may include one or more electrodes in contact with the second medium.
- In exemplary embodiments, the separation of analyte from the liquid sample is desirable as the presence of analyte can then be detected without interference from contaminants (e.g., molecular components such as biological compounds) of the liquid sample. For example, some liquid samples (e.g. blood) produce a non-negligible background electrochemical signal which can interfere with electrochemical determination of certain analytes. Hence separation of analyte from blood may be desirable in order to accurately determine the presence of the analyte.
- A device is provided to perform the method of detecting an analyte. The method of detection is an assay for the presence of analyte in the liquid sample and the device an assay device for that method.
- The assay device is a microfluidic device having a channel network. The network comprises an inlet connected to a first channel portion, which is connected to a second channel portion at a junction (e.g., a capillary stop) at an intermediate position in the channel network. At the junction the second channel portion can have a cross-sectional area that is larger than the first channel portion creating a capillary stop pressure (pcapstop) and forming the capillary stop. The capillary stop can alternatively be formed by other means, such as the use of a hydrophobic patch disposed on one or more interior surfaces of the channel.
- Liquid sample deposited at the inlet can flow into the first channel portion and fill the first channel portion up to the junction. Liquid sample forms an interface (e.g., a liquid sample:second medium interface) proximal to the junction of the first and second channel portions. The second medium is typically another fluid (e.g., a gas such as air, a different liquid such as a buffer) or flowable medium (e.g., a gel, such as an electrophoresis gel). In embodiments, the second medium is a gas and the interface is a liquid sample-gas interface (e.g., a meniscus).
- In some embodiments, the interface is formed by contacting a first interface between (a) one of the liquid sample and the second medium and (b) third medium with the other of the liquid sample and the second medium such that the other of the liquid sample and the second medium displaces the third medium from the first interface. In some embodiments, the third medium is a second liquid (e.g., a buffer) and the device further includes, or is configured to cooperate with, a reservoir of second liquid from which second liquid can be released into the second channel portion to flow towards the junction (e.g., towards the interface). For example, in embodiments where the interface is a liquid sample-gas interface, the second channel portion directs released second liquid to the liquid sample:gas interface to displace the gas (e.g., air) and form a liquid sample:second liquid interface.
- In exemplary embodiments the region of the second channel portion adjacent the junction is configured to direct second liquid transversely across a face of the liquid sample:air interface to progressively decrease the area of the liquid sample:air interface as the second liquid flows across the face of the liquid sample:air interface. Subsequent to forming the liquid sample:second liquid interface, the interface may be essentially static and/or bulk movement of liquid relative to the interface may be absent at least until transport across the interface as described above.
- The configuration of the second channel portion adjacent the interface can include a change in height and/or width of the second channel portion. In exemplary embodiments the configuration of the second channel portion adjacent the interface includes a tapering of the width and height of the second channel portion to increase the second channel portion width and height at the junction. The second channel portion can further include a change of direction proximal to the junction provided by a bend portion in the second channel portion adjacent the junction. An inside wall of the bend portion can further comprise a capillary stop (e.g. a notch or vent in the inside wall and/or a hydrophobic patch), whilst an outside wall of the bend does not have a corresponding capillary stop. Second liquid advancing towards the junction is retarded at the capillary stop on the inside wall of the bend such that the second liquid advances more rapidly around the outside wall of the bend, in which the junction of the first and second channel portions can be located (at least partially). Typically, the portion of second liquid adjacent the outside wall pivots with respect to the capillary stop. This directs the flow of second liquid transversely across the face of the liquid sample:air interface formed at the junction and facilitates formation of a liquid sample:second liquid interface that is substantially free of air bubbles.
- Reagents in the first channel portion form magnetically susceptible particle:analyte complexes with analyte in the liquid sample. These complexes can now be magnetically moved across the liquid sample:second liquid interface and towards a sensor, e.g. one or more electrodes, in the second channel portion where the presence of the analyte can be detected.
- The device is configured for operation in conjunction with a meter or reader into which the device is inserted. The meter includes a magnet, which may be an electromagnet, for magnetically moving the magnetically susceptible particles and complexes. The meter also includes components configured to receive signals from the assay device, and a processor and display for determining and displaying an assay result.
- The device can be configured to detect more than one analyte.
- Assays for determining (e.g. quantitatively or qualitatively) one or more analytes or indicators in sample material (e.g., a biological sample) are described. Typical analytes are biomarkers related to (e.g., indicative of) the presence of a physiological condition in a mammalian subject. The presence of the physiological condition is determined based at least in part on the result of the determination of the biomarker (e.g., by comparing the result to a reference value). Determination of an analyte can be direct or indirect. For example, the presence of an analyte can be indirectly determined by detecting a signal (e.g., an electrochemical or optical signal) resulting from a detectable label (e.g., an enzyme label) conjugated to the analyte. An analyte can be directly determined by, for example, detecting a signal (e.g., an electrochemical or optical signal) resulting from the analyte itself.
- Any of the devices or methods described herein can be further configured or implemented to perform at least one action at least in part based on and/or using a result of the determination. For example, the at least one action can be selected from the group consisting of storing the result, making the result available for further processing, displaying the at least one result, recording the result, transmitting the result to a remote location, comparing the result to a reference value, displaying information related to the result, choosing from among multiple actions based on the result, or combination thereof. Here, the term "result" includes values or indicia indicative of the result.
- For example, an assay may result in the detection or determination of a characteristic or the detection of an analyte. The result of the determination or detection may be further stored, and/or processed and/or recorded and/or transmitted to a remote location and/or compared to a reference value (e.g. a standard subject population reference value or an individual subject reference value (e.g., a baseline determined from one or more prior determinations of the analyte from the patient)) and/or displayed as an assay result (e.g. to a user of the apparatus) and/or acted on (e.g. through the alteration of a therapeutic programme or strategy). Transmission of a determination or detection to a remote location can be carried out by a communications network, e.g. LAN, WAN, and may be via the internet. Transmission can be wireless transmission to a server, host or proxy. Wireless transmission can be implemented using the Bluetooth® transmission protocol.
- The analyte may be any analyte, and more particularly any analyte to which a binding agent, such as an antibody, may be raised and coupled to a magnetically susceptible particle.
- In exemplary embodiments an analyte is a natriuretic peptide such as at least one of BNP or NT-proBNP. NT-proBNP (N-terminal truncated pro-brain natriuretic peptide) is the amino- terminal fragment of BNP (brain natriuretic peptide or B-type natriuretic peptide). BNP is the 32 amino acid (aa) peptide cardiac hormone synthesized by ventricular cells and stored as a 108aa pro-peptide. It is secreted in response to ventricular expansion or pressure overload. The pro-peptide is cleaved to release the 32aa active BNP and a 76aa N-terminal fragment (NT-proBNP). BNP and NT-proBNP are markers of ventricular distension and overload. NT-proBNP is correlated with ambulatory cardiac filling pressures in outpatients with chronic heart failure (Braunschweig et al., European Journal of Heart Failure 8 (2006) 797-803) and is indicated as a biomarker of myocardial stretch and chronic heart failure (Murdoch et al., Am Heart J 138(6):1126-1132, 1999) and as a predictor of mortality in acute heart failure (Sakhuja et al., Clinical Chemistry 53:3 412-420 (2007).
- Exemplary assays for determining a concentration or amount (qualitative or quantitative) of NT-proBNP in a human blood sample can therefore be used in the monitoring, diagnosis, prognosis, assessment of risk of, and/or assessment of susceptibility to a pathological condition or disease wherein, for example, the pathological condition or disease is chosen from a cardiac condition or disease; heart failure; chronic heart failure; congestive heart failure; myocardial infarction; hypertension.
- In other exemplary embodiments the analyte can be chosen from potassium ion, cystatin C, troponin T, troponin I, myeloperoxidase, creatine kinase MB.
- The analyte can be a biomarker for a condition that afflicts the mammalian body. The term "biomarker" refers to a biochemical in the body that has a particular molecular trait to make it useful for diagnosing a condition, disorder, or disease and for measuring or indicating the effects or progress of a condition, disorder, or disease. For example, common biomarkers found in a person's bodily fluids (i.e., breath or blood), and the respective diagnostic conditions of the person providing such biomarkers include, but are not limited to, ischemia modified albumin "IMA" (source: lack of oxygen to the blood; diagnosis: coronary artery disease), N-terminal truncated pro-brain natriuretic peptide "NT pro-BNP" (source: stretching of myocytes; exemplary diagnosis related to congestive heart failure), acetaldehyde (source: ethanol; diagnosis: intoxication), acetone (source: acetoacetate; diagnosis: diet; ketogenic/diabetes), ammonia (source: deamination of amino acids; diagnosis: uremia and liver disease), CO (carbon monoxide) (source: CH2Cl2, elevated % COH; diagnosis: indoor air pollution), chloroform (source: halogenated compounds), dichlorobenzene (source: halogenated compounds), diethylamine (source: choline; diagnosis: intestinal bacterial overgrowth), H (hydrogen) (source: intestines; diagnosis: lactose intolerance), isoprene (source: fatty acid; diagnosis: metabolic stress), methanethiol (source: methionine; diagnosis: intestinal bacterial overgrowth), methylethylketone (source: fatty acid; diagnosis: indoor air pollution/diet), O-toluidine (source: carcinoma metabolite; diagnosis: bronchogenic carcinoma), pentane sulfides and sulfides (source: lipid peroxidation; diagnosis: myocardial infarction), H2S (source: metabolism; diagnosis: periodontal disease/ovulation), MeS (source: metabolism; diagnosis: cirrhosis), and Me2S (source: infection; diagnosis: trench mouth). The biomarker can be a marker of heart failure (e.g. chronic heart failure, heart disease or susceptibility to myocardial infarction (MI), e.g. a marker of MI risk) or a renal marker, e.g. a marker of glomerular filtration rate, which may provide information on blood volume.
- In exemplary embodiments the sample material is a liquid such as a biological liquid (e.g., blood, blood plasma, serum, urine, saliva, mucous, tears, semen, cerebrospinal fluid (CSF), lymph or other bodily fluid). In exemplary embodiments the sample material is a bodily fluid from a mammal (e.g. a human who may be male or female). In exemplary embodiments the sample material is whole blood from a human. The analyte can be any component that is found (or may potentially be found) in the sample, such as, for example, a protein, a peptide, a nucleic acid, a metabolite, a saccharide or polysaccharide, a lipid, a drug or drug metabolite, or other component. The assay device can optionally be supplied with a blood separation membrane arranged between a sample inlet and the detection zone, such that when whole blood is available as a sample, only blood plasma reaches the detection zone.
- Magnetically susceptible particles can include magnetic particles or particles that can be manipulated (e.g., moved) and/or positioned by a magnetic field. The magnetically susceptible particles can be non-magnetic but susceptible to manipulation or positioning by a magnetic field or be magnetic (e.g. a source of a magnetic field lines). The magnetically susceptible particles can be spherical beads and can have a diameter of at least about 0.05 microns, at least about 1 micron, at least about 2.5 microns, and typically less than about 20µm. A magnetically susceptible particle can be, for example, a magnetic particle described, in
U.S. Patent Application Publication Nos. 20050147963 or20050100930 , orU.S. Patent No. 5,348,876 , or commercially available beads, for example, those produced by Dynal AS (Invitrogen Corporation, Carlsbad, California USA) under the trade name DYNABEADS™ and/or MYONE™. In particular, antibodies linked to magnetic particles are described in, for example, United States Patent Application Nos.20050149169 ,20050148096 ,20050142549 ,20050074748 ,20050148096 ,20050106652 , and20050100930 , andU.S. Patent No. 5,348,876 . The magnetically susceptible particles may be ferrous particles. - The magnetic field to which the particles are susceptible can be applied by a magnet, which can be any kind of magnet including a permanent magnet, temporary magnet, or electromagnet. The magnet can be used as a magnetic source for application of a magnetic field towards magnetically susceptible particles.
- In exemplary embodiments components or Iiquid:gas or liquid:liquid interfaces can be positioned proximal to a physical structure. Proximal positioning refers to positioning close to the physical structure. The positioning can be at, or adjacent, the physical structure.
- Exemplary embodiments include a microfluidic device. A microfluidic device can comprise a support in which one or more channels are formed to provide a channel network capable of directing flow, and optionally controlling flow, of liquid through part or all of the network. Typically the channel network will have multiple channel portions. In exemplary embodiments the microfluidic device is configured to perform a desired assay, and can be configured to interact with a meter in order to provide an assay result. The microfluidic device is generally small enough to fit on a laboratory bench, and in exemplary embodiments is small enough to be carried by an individual human user in one or two hands.
- In exemplary embodiments, channels and channel portions are generally enclosed spaces defined by surrounding walls. The channel can have any cross-sectional shape (e.g. rectangular, trapezoidal, or circular). Channels can be in fluid communication with the atmosphere external to the microfluidic device by means of apertures (e.g., inlets, outlets or vents) formed in the channel network. Channels or channel portions can be open to the atmosphere for part or all of their length, e.g. by not having an enclosing lid. Channels or channel portions can comprise a capillary, i.e. a channel of small internal diameter capable of holding or transporting liquid by capillary action, wherein capillary action is (at least in part) the effect of surface tension that draws a liquid into or along the channel.
- Devices according to embodiments can be for use in performing an assay, e.g. on a blood sample. The user can be a human (male or female). In exemplary embodiments the user can perform the assay in the absence of the presence, or in-person assistance, (verbal or otherwise) of a medical practitioner (e.g. nurse, physician, medical doctor, general practitioner, surgeon or phlebotomist). Accordingly, the assay devices can be configured for use away from the hospital, doctor's office, surgery or other medical establishment and can be used in a domestic environment, such as the home or office, or in any convenient location.
- A method and/or device and/or meter can be configured for conduct of an assay and production of an assay result to a user in a total test time of less than about 30 minutes (e.g. less than about 20 minutes, less than about 15 minutes, less than about 10 minutes) and in one embodiment in about 10, 11 or 12 minutes.
- In exemplary embodiments one or more sensors can be used to determine a characteristic of a liquid and/or to detect a signal. The signal can be the presence or absence of a component, e.g. analyte or oxidized compound. In preferred exemplary embodiments the sensor is an electrochemical sensor including one or more electrodes and the signal is an electrochemical signal (e.g., a signal formed by the reduction of an oxidized compound at an electrode, or the oxidation of a reduced compound at an electrode), which can be detected and/or measured amperometrically and/or voltametrically at the electrode(s). Other sensors include detectors of radiation (e.g. light, X-ray, γ-ray radiation) and/or optical (e.g., fluorescence, reflectance, or absorbance).
- In exemplary embodiments components can be bound or conjugated to one another to form complexes (e.g. a magnetically susceptible particle can be conjugated to a binding agent). Binding or conjugation of components can be direct (e.g. binding of an analyte to an anti-analyte antibody) or indirect (e.g. binding of a magnetically susceptible particle to a binding agent through linkers such as streptavidin and biotin).
- In exemplary embodiments binding agents are molecules capable of specifically binding to a selected target with high affinity, having a Kd for the target of about 100µM or less (e.g. less than about 50µM, less than about 10µM, less than about 1µM, less than about 100nM, less than about 10nM, less than about 1nM, less than about 100pM, less than about 10pM). The first and second binding agents can be respectively chosen from an antibody (monoclonal or polyclonal), antibody fragment (e.g. scFV fragment), antibody binding domain, aptamer or other recognition reagent. The first and second binding agents can be different, e.g. an antibody and an aptamer.
- In exemplary embodiments reagents are provided in an assay device (e.g., in dry form). The reagents can be configured to participate in an assay, e.g. to detect presence of analyte, and can be configured to form conjugates and/or bind the analyte. In exemplary embodiments, the reagents include conjugates of magnetically susceptible particle and at least one reagent (e.g., an antibody labeled enzyme) configured to bind the analyte and form a ternary complex with the magnetically susceptible particle. In exemplary embodiments conjugates of magnetically susceptible particle and reagents are configured to participate in a sandwich assay involving first and second binding agents to form a ternary complex.
- Exemplary embodiments provide a device and method for performing an assay on a single small volume blood sample, or other biological materials or complex mixtures.
- Exemplary embodiments will now be described in detail, with reference to the accompanying figures. The invention includes the combination of the features described in the exemplary embodiments except where such a combination is clearly impermissible or expressly avoided.
- Referring to
Fig 1 anassay method 1000 includes amixture formation step 1001, a reagent/analyte capture step 1002, acomplex transport step 1003, acomplex determination step 1004 and a formation of anassay result step 1005. Typically,method 1000 is performed using an assay device including a reagent zone, in which the sample reacts with the reagents, a detection zone in which determination of the analyte is performed (either qualitatively or quantitatively), and an interface zone, which provides an interface between the reagent zone and the detection zone. - In mixture formation step 1001 a mixture including a quantity of sample material (e.g. a sample liquid such as blood from a human) and reagents capable of binding to an analyte is formed. In an exemplary embodiment the reagent capable of binding to the analyte may be an antibody or antibody domain or fragment (e.g. scFv) capable of binding to the analyte. In reagent/
analyte capture step 1002 the reagents capable of binding the analyte form complexes with analyte that is present in the sample. Incomplex transport step 1003 reagent:analyte complexes formed during the previous step may be washed to remove non-complex material and are transported to a detection zone. Incomplex determination step 1004, the presence of reagent:analyte complexes that have been transported to the detection zone is determined (e.g. qualitatively or quantitatively). The assay result is formed instep 1005 as a result of the extent of detection of reagent:analyte complexes in the preceding step. For example, detection of reagent:analyte complexes may be indicative of the diagnosis or prognosis (new or continued) of a disease state or pathological condition of a user or patient. Therefore, the detection of reagent:analyte complexes may be used or processed (e.g. by comparison with a reference value), to provide an assay result, which may be displayed to the user. -
Assay method 1000 will now be discussed in greater detail. - In mixture formation step 1001 a mixture is formed between reagent materials that are disposed within a reagent zone of an assay device and a quantity of sample material sufficient to fill the reagent zone of the assay device. A sample of blood can be obtained from a finger stick or a venous puncture. The volume of blood is typically about 10 µl or about 5µl.
- Several reagents are present within the reagent zone of the assay device. The reagents typically include the following species; magnetically susceptible particles, a first reagent capable of binding to the analyte, a second reagent capable of binding to the analyte concurrently with the first reagent (e.g., as in a sandwich). Typically, the reagent binds to a first unique region of the analyte and the second reagent binds to a second unique region of the analyte. The first reagent is configured to bind to the magnetically susceptible particles even in the absence of analyte (e.g., in a non-specific binding reaction). For example, the first reagent may include a biotin portion and the particle may be coated with streptavidin, which captures the biotin modified first reagent. The second reagent includes a detectable label (e.g., an enzymatic label such as an enzyme). In an exemplary embodiment, the second reagent is a labeled particle (e.g., a non-magnetically susceptible particle such as a colloidal gold sol particle) that is conjugated with a binding reagent for the analyte (e.g., an antibody for the analyte) and with an enzymatic label. Typically, the particle includes multiple enzymatic labels thus increasing the number of enzyme labels that become part of the reagent:analyte complex. The second antibody-enzyme conjugate is typically provided pre-associated with the labeled particles.
- In general, the first and second recognition reagents do not associate with one another in the absence of analyte. The presence of analyte, however, can associate the first and second recognition reagents together, in a ternary complex
The second reagent can recognize the same or a different analyte and can be a binding agent that specifically binds the same or a different analyte. The reagent zones can include further reagents such as redox mediators, substrates for particular enzymes and salts suitable for forming buffer solutions. The second binding agent can be linked to a particle that can induce mobility on the so-formed ternary complex. The particle can be, for example, a polymer microsphere, a metal nanoparticle, or a magnetically susceptible particle. - When the reagents are mobilized by a sample liquid including the analyte, the reagents interact with the analyte to form a complex including the magnetically susceptible particle, the first reagent, the analyte, and the second reagent. The streptavidin coated magnetically susceptible particle can accommodate a number of biotin modified reagents capable of binding to the analyte. Accordingly, each complex may include multiple analyte molecules and multiple second reagents.
- The reagent zone may include one or more additional reagents such as, for example, an anti-coagulant to inhibit clotting of blood within the reagent zone and/or buffer salts. Buffer salts present in the reagent zone control the pH of the mixture to give a pH value that favours the formation of complexes. The pH value is maintained at a desired pH, for example the pH may be maintained within a range of between about pH 7.2 and about pH 7.6.
- Reagent/
analyte capture step 1002 includes forming complexes between the reagents and analyte contained within the sample. When a sample is applied to the assay device, the dried reagents initially form an inhomogeneous mixture with the sample. Within a short interval of time, the reagents become sufficiently hydrated that they begin to interact with the sample. The first and second antibodies bind to analyte and form complexes. The biotin labeled first reagent binds to the streptavidin coated magnetically susceptible particle(s). The second reagent (e.g., a non-magnetically susceptible particle conjugated to an enzyme label and a binding agent for the analyte) binds the analyte. - Complex transport/
wash step 1003 includes moving the reagent:antibody complexes from the reagent zone to the detection zone. The detection zone is filled (e.g., actively) with a buffer solution during the course of a sample assay. Buffer is released from a reservoir at a predefined time after sample has been applied to the assay device. Buffer solution fills the detection zone and the interface zone. When buffer solution is delivered into the interface zone, the buffer forms a sample liquid:second liquid interface with the sample in the reagent zone (as will be described in more detail below). Excess buffer solution moves in to an overflow channel. When buffer has made contact with and formed an interface with the - sample there is a continuous liquid path through the microfluidic network of the assay device. The reagentranalyte complex can thus be moved along the length of the assay device supported in a continuous liquid stream.
- A magnetic field can be used to manipulate the reagent:analyte complex within the assay device. The reagent:analyte complex can be drawn along the reagent zone, through the interface zone to the detection zone by a magnetic field. The path of the magnetic field moves in a direction that transfers magnetically susceptible particle complexes from the reagent zone to the detection zone.
- In some embodiments, one or more of the detection zones include one or more electrodes. The electrodes can be formed of a material selected for electrical conductivity and low reactivity with sample components, for example, silver, gold, aluminum, palladium, platinum, iridium, a conductive carbon, a doped tin oxide, stainless steel, or a conductive polymer. The electrodes in the detection zones (the working electrodes), in conjunction with second electrodes in the reference zones (the reference electrodes) can measure an electrical property of the sample, such as a voltage or a current. Alternatively, the detection zones and the reference zones can each have at least one working electrode and counter electrode. That is, the detection and reference zones can make independent measurements. Optionally, counter electrodes are also included in the assay device. Assay devices including electrodes for measuring electrical properties of a sample are described in, for example,
U.S. Patent Nos. 5,708,247 ,6,241,862 , and6,733,655 . - In some embodiments, the assay device base, assay device lid, or both have a translucent or transparent window aligned with the detection zone. An optical change that occurs in the detection zone can be detected through the window. Detection can be done visually (i.e., the change is measured by the user's eye) or measured by an instrument (e.g., a photodiode, photomultiplier, or the like). In general, the reference zone is similar in nature to the detection zone. In other words, when the detection zone includes an electrode, the reference zone can likewise include an electrode. When the detection zone is aligned with a window for optical measurement, the reference zone can similarly be aligned with a window for optical measurement. In some embodiments, the reference zone is not adapted to collect analyte. Alternatively, the reference zone is adapted to collect analyte, but performs a different analysis on said analyte. Thus, the detectable change measured in the reference zone can be considered a background measurement to be accounted for when determining the amount or concentration of analyte present in the sample.
- During
complex determination step 1004 magnetically susceptible reagent:analyte complexes that have been transferred to the detection zone can be measured. In an exemplary embodiment the detection zone includes electrodes that can be used to perform an electrochemical analysis of the sample. The enzyme labeled second reagent that is part of reagentranalyte complex can convert a substrate present in the buffer used to fill the detection zone. The substrate can be converted from a first form that is not detectable to a second form that is detectable. A measurement electrode within the detection zone can be used to measure the detectable form of the substrate. For example, an amperometric measurement can be made, in which a working electrode is polarised at a certain potential versus a reference electrode e.g. a silver/silver chloride (Ag/AgCl) reference electrode. For example, potassium ferricyanide can be converted (reduced) to potassium ferrocyanide by glucose oxidase during the conversion of glucose to gluconic acid. Any potassium ferrocyanide formed can be measured at about +400 mV vs Ag/AgCl as a positive current. The ferrocyanide is re-oxidised back to ferricyanide by the working electrode. An electroactive species can be oxidised, in which case it loses electrons to the electrode, or reduced, in which case it receives electrons from the electrode. The transfer of electrons between the electrode and the electroactive substance results in a measurable current, which may be a positive or negative current. - An amperometric measurement of an electroactive substance can be used to construct a calibration line. A known amount of substance yields a unique current, which can be described by the equation
- The buffer contained within the reservoir of the assay device includes a buffer salt and a substrate for the enzyme. The buffer salt buffers the pH to provide an environment suitable for the enzyme to convert the substrate to a product which can be detected. For example, the buffer salt may be an acetate buffer (e.g., sodium acetate). In some embodiments, the buffer can include at least about 100 mM sodium acetate (e.g., at least about 110 mM sodium acetate). The buffer solution can also contain a chloride salt to stabilise the electrochemistry of the reference electrode during analysis (e.g. potassium chloride (KCl)). In some embodiments the chloride salt can include at least about 100 mM KCl (e.g. at least about 125mM KCl). The buffer solution can also include a detergent to reduce the likelihood of antibody complexes from adhering to the internal surfaces of
microfluidic network 508. In an exemplary embodiment the buffer solution includes 0.1% (v/v) Tween-20™. The buffer also includes substrate(s) for the enzyme label, which in the case of horse radish peroxidase is 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) and hydrogen peroxide (H2O2). In some embodiments the buffer contains at least about 5mM ABTS and at least about 5mM H2O2. - The enzyme label that is conjugated to second binding agent can be horse radish peroxidase (HRP), for example. HRP catalyses the conversion of hydrogen peroxide and ABTS to water and oxidised-ABTS. Any oxidised-ABTS that is produced can be measured electrochemically at a working electrode. Therefore during
complex determination step 1004 any reagent:antibody complexes that have been transported through the microfluidic network of assay device can be measured according to the amount of oxidised-ABTS that is produced in the proximity of a measurement electrode. The measured current is proportional to the amount of oxidised-ABTS according to Eq. 2 and hence the measured current is proportional to the amount of analyte in the complexes that have been transported to the electrode. - In forming an
assay result step 1005, the measurement result obtained duringcomplex determination step 1004 is used to determine an assay result. In exemplary embodiments the assay result comprises displaying or communicating a value or signal indicative of the amount or concentration (quantitative or qualitative) of analyte detected in the assay. In exemplary embodiments the assay result comprises determining the status of the user, as regards the analyte. Depending on the analyte under investigation an elevated measurement result can indicate a diagnosis or prognosis for a disease state or pathological condition associated with the analyte. - In forming an assay result step 1005 a user of the assay device can be presented with information. If the user is qualified to make a clinical judgment (such as a medical doctor) the information might be different compared with a non qualified person, such as a user performing a self-test measurement. A health care professional will typically want numerical data that will facilitate a prognosis or provide a diagnosis. An end user will typically want reassurance that "the way they feel" is a consequence of (i) an unrelated issue, e.g. indigestion or (ii) occurrence or re-occurrence of heart failure, in which case they will be prompted to dial 911, for example.
- Referring to
Figures 3-11 , an exemplary embodiment of the assay device is shown. The assembled device is shown inFig. 3 . Referring toFigures 3 and6 , the assay device is a microfluidic device in which a channel network is formed. The device has a base 502 that can be formed from a plastics substrate, such as polycarbonate in which the channel network can be formed by techniques well known to persons skilled in the art such as moulding, laser ablation or milling of the substrate (as described above). - The device has a laminate structure (as shown in
Fig.6 ) being made up of multiple layers. The microfluidic network is defined by a three layer laminate in which afirst substrate layer 502 is joined to athird substrate layer 506 by asecond substrate layer 504 comprising an adhesive strip, as described above. In an exemplary embodiment a further adhesive strip joins thethird substrate layer 506 with apacking piece 3502 to form a device having five laminate layers. The packing piece has a cut-outsection 3511 configured to permit a magnet inmeter 400 to be positioned in close proximity with the external surface of thethird substrate layer 506. - The
first substrate layer 502 further comprises a raisedannulus 3510 having aliquid inlet 520 proximal its centre and asharp projection 3506 positioned at or adjacent the inlet. An O-ring seal 2402 is seated on or adjacent the annulus and a liquid containingreservoir 507 is received in the annulus, a wall of which is positioned adjacent the sharp element orprojection 3506. - Referring to
Fig.s 4 and10D , thesharp projection 3506 is formed as part of thesubstrate 502. In an exemplary embodiment theprojection 3506 has a pyramid structure the apex of which forms thesharp point 3506 which facilitates puncture ofreservoir 507. In an exemplary embodiment the sharp projection is an integral part ofsubstrate 502 and both may be moulded from plastics material. The sharp projection is located adjacentliquid inlet 520, wherein the entrance toliquid inlet 520 is formed by an aperture in one side of the pyramid structure.Projection 3506 projects into the centre of the space defined by the raisedannulus 3510 and towards a base wall of thereservoir 507 when received in the annulus. In other embodiments thesharp projection 3506 can be made of metal (e.g. steel) or plastics material. - In exemplary embodiments the
reservoir 507 is a pouch having a wall, e.g. a base wall, that may be ruptured bysharp projection 3506 on theassay device 500. In one exemplary embodiment the base wall has a generally smooth outer surface which may be generally planar or convex. - Referring to
Fig.13 , in an exemplary embodiment a seal or gasket (e.g. an O-ring seal) 2401, e.g. of about 400-600µm thickness, having an internal diameter sufficient to encompass the sharp projection and inlet 520 (e.g. at least about 1.5mm, at least about 2mm, at least about 3mm, less than about 5mm, less than about 4mm) is formed or placed around thesharp projection 3506 such that when thereservoir 507 is compressed against the assay device and toward the sharp projection 3506 a gas-tight seal is formed between the reservoir and the assay device preventing air from entering the assay device via theinlet 520 such that liquid in thesecond channel portion 4304 is substantially free of air or other gas bubbles. - In an
exemplary embodiment seal 2401 is integrally formed with thesubstrate 502 and is a raised circular ridge encompassing thesharp projection 3506 andliquid inlet 520. In operation,buffer pouch 507 is pushed towards thesharp projection 3506 so as to rupture the buffer pouch and release liquid. The surface of thebuffer pouch 507 adjacent the sharp projection is urged againstseal 2401 to form an air-tight seal around the sharp-projection 3506. The liquid forced frombuffer pouch 507 and enteringinlet 520 is therefore substantially free of air, or gas bubbles. Accordingly, a slug of liquid is forced intosecond channel portion 4304 and towards thejunction 4305. The absence of air, or large gas bubbles, in the slug of liquid helps form a stable liquid:liquid interface atjunction 4305 and provides for high performance electrochemical detection at the working electrode. - In some exemplary embodiments the
reservoir 507 is made from plastics and/or metal foil material and sealed to form a pouch, bag or sachet containing liquid, e.g. buffer liquid. Thereservoir 507 can be made from first and second materials, wherein one of the materials is softer and/or thinner than the other, the softer or thinner material forming at least part of the wall that is configured for rupture by thesharp projection 3506 on theassay device 500. In one exemplary embodiment thereservoir 507 has a volume of about 40µl (e.g. at least about 50µl, at least about 60µl, less than about 100µl). - In one exemplary embodiment the
reservoir 507 is made from a first material (e.g. plastics material) and a second material (e.g. metal foil such as aluminium foil). The reservoir is dome-shaped having an upper convex part formed by the first material and a lower planar part made from the second material and forming the base of the dome. The planar part is thin (e.g. at least about 20µm thickness) and can be punctured when forced towards the sharp projection. The lower planar part is positioned adjacent the sharp projection. Application of force to the upper convex part forces the lower planar part and sharp projection together, rupturing the reservoir and releasing fluid intoinlet 520. The lower planar part is pushed against the seal located around the sharp projection and inlet to prevent air mixing withfluid entering inlet 520. - Referring to
Fig 7 , an exemplary embodiment of the device has aninlet 510 at one end of the strip, theinlet 510 is connected to thechannel network 508 such that sample liquid received at the inlet can enter the channel network. Thechannel network 508 has afirst channel portion 4302 forming a reagent zone. In an exemplary embodiment thefirst channel portion 4302 is connected directly to theinlet 510. In other exemplary embodiments, aninlet channel 4303 connects theinlet 510 andfirst channel portion 4302. - The
first channel portion 4302 is connected to asecond channel portion 4304 at ajunction 4305. In an exemplary embodiment the plane of the junction is substantially orthogonal to the main longitudinal axis of the second channel portion. The first and second channel portions can have a common longitudinal axis. - The
first channel portion 4302 is generally rectangular in cross-section, although it may have a different cross-sectional shape, e.g. circular. At thejunction 4305 thefirst channel portion 4302 has a cross-sectional area A1 which is less than the cross-sectional area A2 of thesecond channel portion 4304 at thejunction 4305. The difference in cross-sectional area of the first and second channel portions at thejunction 4305 provides a capillary stop 530, as described above. A liquid sample deposited atinlet 510 flows into first channel portion 4302 (e.g. by capillary action) and on reaching the capillary stop 530 the liquid sample meniscus forms a liquid sample:air interface with air contained in the second channel portion. The interface is positioned proximal thejunction 4305. Cross-sectional area A1 is at least about 0.375mm2 and A2 is about 4.67mm2. The ratio of A1:A2 is about 1:12. - Referring to
Figures 7 and8 , adjacent thejunction 4305, the second channel portion has a taperedneck region 4306 in which the width and height of thesecond channel portion 4304 increases when moving along the second channel portion from theliquid inlet 520 towards thejunction 4305. The taperedneck region 4306 provides an increase in the width of the second channel portion from width w6 distal tojunction 4305 to width w5 at thejunction 4305 and an increase in the height of the second channel portion from height h3 distal to thejunction 4305 to height h2 at thejunction 4305. - Referring to
Figure 8 , the taperedneck region 4306 of the second channel portion further comprises a bend portion in which the flow path defined by thesecond channel portion 4304 is changed from a direction that is substantially toward thejunction 4305 to one that is substantially across thejunction 4305. The bend portion is formed by aninside wall 4307 and anoutside wall 4308 of thesecond channel portion 4304. Theoutside wall 4308 contains acorner 536 and theinside wall 4307 has ameans 532 to retard the flow of liquid towards thejunction 4305. The means 532 can be a capillary stop. Theoutside wall 4308 also comprises, at least partially, thejunction 4305 of the first and second channel portions. - Between the
corner 536 and thecapillary stop 532 the base of the second channel portion has a slope orchamfer 534 which connects aregion 4309 of thesecond channel portion 4304 that is distal to thejunction 4305 and has height h3 with aregion 4310 of thesecond channel portion 4304 that is proximal thejunction 4305 and has height h2, wherein h2>h3. Theslope 534 extends obliquely across the second channel portion from a region proximal thecapillary stop 532 towards the opposing channel wall andcorner 536. The upper edge ofslope 534 extends from a region proximal thecapillary stop 532 at theinside wall 4307 of the bend portion across thesecond channel portion 4304 slanting forwards towards thejunction 4305. The upper edge ofslope 534 extends from the region near thecapillary stop 532 obliquely forwards towards thejunction 4305 and towards a region of the second channel portion having a greater width. The lower edge ofslope 534 contacting theregion 4310 ofsecond channel portion 4304 having height h2 makes an angle of about 20° (e.g. at least about 15°, at least about 30°, at least about 35°, less than about 45°, less than about 40°) with the plane ofjunction 4305. The oblique direction of the slope across the second channel portion towards the junction can thus also be described as an oblique slant of about 70° (e.g. at least about 75°, at least about 65°, at least about 60°, at least about 55°, less than about 45°, less than about 50°) from a main width w2 of thesecond channel portion 4304, wherein the main width w2 is perpendicular to the main longitudinal axis of thesecond channel portion 4304 extending towards thejunction 4305. - The upper edge of slope 534 (distal to junction 4305) at its most distal from the junction, and in the region of
capillary stop 532, is about 2.5mm from the wall of thesecond channel portion 4304 in which thejunction 4305 is formed in a direction along a line parallel to the main longitudinal axis of the second channel portion. This distance d2 is about 2.5mm (e.g. at least about 2.0mm, at least about 3.0mm, less than about 5.5mm, less than about 5.0mm). The distance between lower edge of slope 534 (proximal to junction 4305) at its most distal from the wall of thesecond channel portion 4302 in which thejunction 4305 is formed, and in a direction along a line parallel to the main longitudinal axis of thesecond channel portion 4304, is called d3 and is about 0.5mm (e.g. at least about 0.4mm, at least about 1.0mm, less than about 2.0mm, less than about 1.8mm). The shortest distance from the upper edge ofslope 534 to the lower edge ofslope 534 is d4, which is about 2.0mm (e.g. at least about 1.5mm, at least about 2.5mm, less than about 3.0mm, less than about 3.5mm, less than about 4.0mm). - The
slope 534 has an angle of inclination θ of about 8° (e.g. at least about 5°, less than about 15°, less than about 25°), being the angle of inclination of theslope 534 from the base of thesecond channel portion 4304 adjacent thejunction 4305 and having height h3. -
Slope 534 andcapillary stop 532 control movement of liquid through thesecond channel portion 4304 fromliquid inlet 520 towardsjunction 4305. Liquid moving through thesecond channel portion 4304 fromliquid inlet 520 towardsjunction 4305 has an advancing liquid meniscus forming a liquid:gas interface that is advancing towardsjunction 4305. Prior to reachingjunction 4305 the advancing meniscus encounterscapillary stop 532 which retards the movement of the advancing liquid meniscus along theinside wall 4307 of the bend portion.Capillary stop 532 thus acts to steer the liquid:gas interface around the corner in whichcapillary stop 532 is located, as described above. The advancing liquid:gas interface thus moves downchamfer 534 and across the face of thejunction 4305 of the first and second channel portions. - When a liquid sample is contained in the
first channel portion 4302 forming a liquid sample:air interface at the junction, movement of liquid through the second channel portion towards thejunction 4305 and across the face of thejunction 4305 acts to displace the air from the liquid sample:air interface and form an interface of the liquid sample and liquid contained in the second channel portion, e.g. buffer liquid. - The bend portion,
capillary stop 532 andslope 534 act together to advance the flow of liquid in thesecond channel portion 4304 towards thejunction 4305 initially around theoutside wall 4308 of the bend portion andpast corner 536, thereby directing liquid flow across the wall in which thejunction 4305 is formed. This acts to displace air from the liquid sample:air interface and form the liquid sample:liquid interface with minimum retention of air bubbles at the interface. Excess liquid flowing in the second channel moves intooverflow channel 524 until it reachesvent 526. - A liquid sample:liquid interface is thereby formed at the
junction 4305 by flowing liquid in thesecond channel portion 4304 across a face of the liquid sample:air interface so as to displace the air from that interface and progressively decrease the area of the liquid sample:air interface until the air is displaced and the liquid sample:air interface is replaced by a liquid sample:liquid interface. - During flow of liquid in the
second channel portion 4304 across the liquid sample:air interface, liquid sample in the first channel portion is held substantially static. Once the liquid sample:liquid interface is formed and flow of liquid in thesecond channel part 4304 andoverflow 524 has stopped the liquid sample:liquid interface is also substantially static with no bulk movement of liquid occurring across the interface, in either direction. - To avoid breach of the liquid:air interface, e.g. where liquid in the first channel portion breaches the capillary stop formed at the
junction 4305 and enters thesecond channel portion 4304, the capillary stop formed atjunction 4305 is designed to withstand normal capillary forces exerted by the sample fluid. However, the capillary stop can be breached if the force of the sample fluid flowing in the first channel portion is further increased, which may happen if excess sample is applied at the inlet or an external force is applied to the assay device. - It is also preferred that the liquid:liquid interface is stable and substantially static. In particular, the passive movement of particles across the interface, e.g. from the liquid sample into the buffer liquid, should be kept to a minimum, e.g. in order to avoid unwanted cross-reaction of buffer substrate with components of the liquid sample and to minimise loss of magnetically susceptible particles from the liquid sample into
overflow 524. - Prevention or reduction of interface breach can be provided in one or a combination of ways. According to the invention, and referring to
Figure 14 , the height (h'1) of thefirst channel portion 4302 at thejunction 4305 is less than the height (h1) of the main body of the first channel portion 4302 (i.e. h1>h'1). The base of thefirst channel portion 4302 includes a ramp extending upwards towards the junction 4305 (as shown in Figure 21), or alternatively (or additionally) extending downwards towards thejunction 4305 from the lid of thefirst channel portion 4302. The ramp connects the parts of the first channel portion having heights h1 and h'1. Thefirst channel portion 4302 thus has restricted dimensions at thejunction 4305 compared to the main body of the channel. - The reduction in height of the
first channel portion 4302 from h1 to h'1 has the effect of increasing the difference in height between the height of thefirst channel portion 4302 at junction 4305 (this being h'1) and the height of thesecond channel portion 4304 at junction 4305 (h2). This increases the capillary stop. - In combination with, or as an alternative to, the use of a change in height of the
first channel portion 4302 proximal thejunction 4305 one or more of the internal wall(s) (optionally including base and/or lid) of the first channel portion can be coated in a hydrophobic material at, and or proximal to, thejunction 4305. This coating can be in the form of a hydrophobic patch, line or ring extending around the circumference of the first channel portion. The patch, line or ring can have a thickness of about 3mm (e.g. at least about 0.5mm, at least about 1mm, at least about 2mm, at least about 3mm, at least about 5mm). - The possibility of interface breach occurring can also be prevented or reduced by controlling the quantity of sample fluid deposited at the
inlet 510. Sample fluid deposited atinlet 510 and in fluid connection with sample fluid in thefirst channel portion 4302 provides a head of pressure and the capillary stop pressure provided atjunction 4305 is required to equal or exceed this in order to provide a stable liquid:air interface. In some embodiments deposit of an excess of sample fluid is prevented by partitioning the inlet into at least two compartments. One or more first compartments are in fluid connection with thefirst channel portion 4302 and, in combination with thefirst channel portion 4302, have a predetermined total volume (Vi) configured to provide a head of pressure that will not exceed the capillary stop pressure atjunction 4305. In a preferred embodiment Vi is about 5µl or about 10µl (e.g. at least about 2µl, at least about 5µl, at least about 10µl, less than about 30µl, less than about 20µl, less than about 15µl). Excess sample fluid deposited at the inlet overflows from the first compartment(s) into one or more second compartments not fluidly connected to thefirst channel portion 4302. - In an exemplary embodiment where the liquid sample is blood a filter is positioned at
inlet 510 to prevent entry of red blood cells intofirst channel portion 4302 but allow entry of the fluid parts of the blood sample. - In an exemplary embodiment the use of a second liquid introduced to the second channel portion of
assay device 500 to form the liquid sample:liquid interface is replaced by inclusion of a flowable media in the second channel portion. On introduction of the liquid sample to the first channel portion 4302 a liquid sample:flowable media interface is formed proximal thejunction 4305. Magnetic transfer of magnetically susceptible particles across the interface into the flowable media and to the working electrode is then performed as described herein with respect to the other embodiments described. In such embodiments theassay device 500 does not require integration ofreservoir 507. - The flowable media can be a liquid. However, in exemplary embodiments, the flowable media is a viscous liquid or gel. For example, the gel can be a matrix or electrophoresis gel such as an agarose or polyacrylamide gel, or other crosslinked polymer. The gel should provide a continuous flowable media path between the interface and sensor (
e.g. working electrode 516w) allowing for movement of magnetically susceptible particle:first binding agent:analyte complexes from the interface through the gel to the sensor. The gel can also contain substrates (e.g. ABTS and H2O2) required to detect analyte at the sensor. - The
first channel portion 4302 contains reagents. The reagents include multiple magnetically susceptible particles (e.g. at least about 50, at least about 100, at least about 150 magnetically susceptible particles) and a first binding agent configured to bind an analyte. The first binding agent is configured to also bind to the magnetically susceptible particles such that complexes of analyte:first binding agent:magnetically susceptible particle can be formed when the reagents are contacted with a liquid sample containing the analyte. These complexes can be magnetically moved through the liquid sample:liquid interface. - In one exemplary embodiment the reagents include a second binding agent configured to bind the analyte at a different spatial location (epitope) on the analyte to the first binding agent. The first and second binding agents can both be bound to an analyte molecule at the same time to form a "sandwich" complex. The sandwich complex can comprise first and second binding agents bound to the analyte and magnetically susceptible particle bound to the first binding agent. These complexes can be magnetically moved through the liquid sample:liquid interface.
- The first or second binding agent can be conjugated to a detectable marker. The detectable marker can be any detectable label, e.g. enzyme label, fluorescent marker, radiolabel. An enzyme label can provide or cause a detectable signal, e.g. an electrochemical signal - oxidation or reduction at an electrode - following interaction with a substrate of the enzyme. A fluorescent marker can provide an optical signal - fluorescence - which can be detected by an optical sensor or scintillation counter. A radiolabel can provide an electromagnetic signal which can be detected by a sensor that can detect the electromagnetic radiation.
- In an exemplary embodiment, the second binding agent is conjugated to an enzyme label, e.g. horse radish peroxidise. Second binding agent:enzyme label conjugates are further absorbed onto a colloidal sol particle, e.g. colloidal gold sol particles. The colloidal sol particles can have a diameter of about 20nm or about 40nm.
- The magnetically susceptible particles and first binding agent are modified to incorporate complementary linkers, e.g. one of biotin and streptavidin, in order to provide conjugates of the magnetically susceptible particles and first binding agent. The magnetically susceptible particles and first binding agent can be deposited in the first channel portion in pre-conjugated form, or can be deposited separately such that the conjugates form on mixing of the reagents in the liquid sample.
- In an alternative exemplary embodiment a mixture of liquid/fluid reagents is introduced to the
first channel portion 4302 and is then dried to provide a dry mixture reagent deposit. - In an exemplary embodiment, the analyte for detection in a blood sample contained in the first channel portion is NT-proBNP (e.g. human NT-proBNP). The first and second binding agents are anti-NT-proBNP antibodies that bind different epitopes on NT-proBNP. The first binding agent is:
- a monoclonal mouse anti-human NT-proBNP antibody 15C4 (HyTest Ltd., Intelligate 6th floor, Joukahaisenkatu 6, 20520, Turku Finland; Catalogue #:4NT1) and the second binding agent is chosen from:
- monoclonal mouse anti-human NT-proBNP antibody 15F11 (HyTest Ltd., Intelligate 6th floor, Joukahaisenkatu 6, 20520, Turku Finland; Catalogue #:4NT1);
- monoclonal mouse anti-human NT-proBNP antibody 29D12 (HyTest Ltd., Intelligate 6th floor, Joukahaisenkatu 6, 20520, Turku Finland; Catalogue #:4NT1).
- The first binding agent can be biotinylated to facilitate conjugation to streptavidin coated magnetically susceptible particles. The second binding agents can be conjugated to horse radish peroxidise and 20nm or 40nm diameter colloidal gold sol particles.
- Other antibodies to NT-proBNP are publicly available, e.g. those available from HyTest Ltd., Intelligate 6th floor, Joukahaisenkatu 6, 20520, Turku Finland, e.g. monoclonal mouse anti-human NT-proBNP antibodies 5B6, 7B5, 13G12, 11D1, 16E6, 15D7, 24E11, 28F8, 18H5, 16F3 (Catalogue #:4NT1).
- In an exemplary embodiment in the
electrode set second channel portion 4304 the workingelectrode 516w is positioned closest thejunction 4305 at a distance of about 3.6mm to the centre line of the electrode from the junction (e.g. at least about 2mm, at least about 3mm, at least about 3.5mm, at least about 4mm, at least about 5mm, at least about 6mm, less than about 8mm, less than about 10mm).Electrode 516w has a width of about 2.4mm (e.g. at least about 2.0mm, at least about 2.5mm, less than about 3.5mm, less than about 3.0mm). The width ofelectrode 516w is sufficient to tolerate small variations in the positioning of magnetically susceptible particles and retain the ability to detect an electrochemical signal produced by reagent-substrate interaction at those particles. Between the working electrode andreference electrode 516r is acounter electrode 516c. The working and counter electrodes are made from carbon paste and the reference electrode from silver paste. The reference electrode is an Ag/AgCl reference electrode and is about 1mm wide (e.g. at least about 0.6mm, at least about 0.8mm, less than about 2.0mm, less than about 1.4mm, less than about 1.2mm) and about 5mm from the centre line of the electrode from the junction 4305 (e.g. at least about 4mm, at least about 6mm, less than about 9mm, less than about 12mm). - In one exemplary embodiment the enzyme label is horse radish peroxidase and the liquid in the
second channel portion 4304 is a reaction buffer containing sodium acetate buffer, hydrogen peroxide substrate, and theredox mediator 2,2'-azino-bis-(3-ethylbenzo-thiazoline-sulfonic acid) (ABTS), as described above. In one exemplary embodiment the buffer liquid is 10mM ABTS, 10mM H2O2, 150mM KCl, 125mM sodium acetate; 0.1% v/v Tween-20™ , made to a final pH 4.2. - In other embodiments where detection of analyte in the second channel portion is other than by electrochemical detection - e.g. detection of fluorescence or colour - the sensor may comprise a region of the second channel portion at which a signal, e.g. fluorescence or colour, can be detected. In such embodiments the sensor can comprise a transparent portion of the device permitting interaction with a detector, e.g. a photodetector or scintillation counter, in
meter 400. - The device can have one or more "on-board controls" to serve as checkpoints for the proper operation of the device. For example, a first on-board control can be the use of one of the
electrodes liquid inlet 520 towards thejunction 4305. Flow of liquid through thesecond channel portion 4304 will form a conductive bridge between two of theelectrodes meter 400 during liquid flow through thesecond channel portion 4304 towards thejunction 4305 to detect current flow through two electrodes, e.g. the working andcounter electrodes junction 4305. Referring toFigure 16A , a second on-board control can be the use of an electrode orelectrode pair 3601 positioned inoverflow channel 524 to detect flow of liquid into the overflow channel and provide an indication of liquid sample:liquid interface formation atjunction 4305. - Further on-board controls can act as controls for the assay being performed. For example, because substrates or reagents can decompose or lose activity over time, one may wish to test for activity of these substrates or reagents, e.g. of a substrate contained in liquid introduced into the
second channel portion 4304. In one exemplary arrangement the enzyme label can be horse radish peroxidase, which catalyses conversion of hydrogen peroxide and ABTS to water and oxidised-ABTS. Hydrogen peroxide and ABTS are provided in the buffer liquid introduced to thesecond channel portion 4304. Referring toFigure 16B , the presence and/or activity of the hydrogen peroxide and ABTS can be verified by immobilizing a predetermined quantity of the horse radishperoxidase enzyme label 5501 at electrode(s) 3601 in theoverflow channel 524. Active buffer liquid components reaching the overflow will be catalysed and produce oxidized ABTS and an electrochemical signal that can be detected by electrode(s) 3601. Detection of a signal is indicative of active buffer components and serves to verify the validity of the determination made at workingelectrode 516w. Referring toFigure 16C , in an alternative arrangement the immobilized horse radish peroxidase can be substituted for an immobilized complex of magnetically susceptible particle:first binding agent:analyte:second binding agent, wherein the horse radish peroxidase is conjugated to the second binding agent. Such an arrangement may more accurately reflect the form of ternary complex formed at the workingelectrode 516w and provide an improved control. - Variations of the controls illustrated in
Figures 16B and 16C are illustrated inFigures 15A and 15B respectively. Referring toFigure 15A , first and second electrodes (or pairs of electrodes) 5405, 5406 are provided in theoverflow channel 524. A predetermined amount of horse radish peroxidase is immobilized 5401 at thefirst electrode pair 5405 and will produce a first electrochemical signal R1 when buffer liquid containing hydrogen peroxide and ABTS is present. A second predetermined amount of horse radish peroxidase is immobilized 5402 atelectrode pair 5406, wherein the second amount is larger than the first amount atelectrode 5401. The second amount of horse radish peroxidase will produce an electrochemical signal R2 when buffer liquid containing hydrogen peroxide and ABTS is present, where R2>R1. R2 and R1 can be configured to provide high and low control electrochemical signals, with respect to the selected assay and provide verification of the operable range of the assay. Referring toFigure 15B , in an alternative arrangement the immobilized horse radish peroxidase can be substituted for an immobilized complex of magnetically susceptible particle:first binding agent:analyte:second binding agent, wherein the horse radish peroxidase is conjugated to the second binding agent. Such an arrangement may more accurately reflect the form of ternary complex formed at the workingelectrode 516w and provide an improved control. - In a microfluidic assay involving the interaction of a substrate with reagents in a fluid or liquid, on-board controls can be used to assess the state of the substrate(s) and/or reagent(s). For example, they can validate the activity of the substrate(s) and/or reagent(s) such that a valid assay result can be obtained. In another example, they can indicate that one or more of the substrate(s) and/or reagent(s) have lost or gained an activity or chemical state (e.g. oxidized/reduced), indicating that the assay result will not be valid within normal parameters and may need to be deemed void or be corrected. On-board controls of this kind can be performed independently of the presence of the sample, and provide information on the reagents and substrates used in the assay device.
- In exemplary embodiments of the assay device, in which reagent(s) interact with sample in a first zone and are then moved into a different media, e.g. different liquid or fluid, in which the reagent(s) interact with substrate(s) resulting in a signal that is detected at different zone, an on-board control that indicates the activity or viability of the reagent(s) and/or substrate(s) is provided. In exemplary embodiments electrochemical detection of substrate and/or reagent activities is used to provide control values. In exemplary embodiments where dry reagent or substrate is used in the assay the on-board control will use a corresponding dry reagent or substrate, which may be re-hydrated prior to detecting the control signal.
- The on-board control for activity of the reagents comprises a predetermined quantity of reagent, e.g. enzyme reagent, deposited at or adjacent a defined location in the
microfluidic network 508. In an exemplary embodiment this quantity of reagent is deposited at the same time as reagent is deposited in the reagent zone for interaction with the sample and is from the same batch of reagent. The reagent is deposited in thesecond channel portion 4304 at a location downstream of thejunction 4305 with respect to the direction of flow of the second liquid, i.e. in theoverflow 524. This reagent control is positioned in theoverflow channel 524 such that reaction of the reagent and substrate does not affect or interfere with signal detection at the workingelectrode 516w which relies on the interaction of reagent bound to magnetically susceptible particles from the sample with substrate in the second liquid. - A predetermined quantity of reagent is deposited in the
overflow 524 at or adjacent a reagent control zone. According to the invention the reagent control zone has one ormore detection electrodes 3601, e.g. a set of three electrodes (working, counter and reference), to detect the reagent control signal. Following formation of the liquid sample:second liquid interface and flow of the second liquid into theoverflow 524, substrate contained in the second liquid reacts with reagent at the reagent control zone to produce a signal that is detected bymeter 400. - The signal may be electrochemical or optical, for example. In an exemplary embodiment the reagent is horse radish peroxidase (HRP) and substrates are ABTS and H2O2. The reaction of HRP with ABTS and H2O2 yields oxidized ABTS which can be electrochemically detected by the electrode set. Accordingly, the extent of oxidation of ABTS (and effectively loss of active (reduced) ABTS for conversion to oxidized ABTS by reaction with reagent) can be detected in the second liquid at the working electrode prior to interaction with reagent to provide a substrate control.
- In an exemplary embodiment a substrate control is also provided. The activity of the substrate may be determined at any chosen location in the second channel portion 4304 (or in a further channel portion provided for this purpose) provided that location is substantially free of reagent. In an exemplary embodiment the activity of the substrate is determined in the second liquid upstream of the
junction 4305 and prior to transfer of magnetically susceptible particles across thejunction 4305 into the second liquid. Accordingly, the substrate control signal indicates activity of the substrate in the absence of reagent. In an exemplary embodiment the substrate control signal is determined atelectrodes - Determining a control signal for substrate activity in the absence of reagent provides a signal for the substrate at zero reagent concentration (i.e. [R]=0). Determining a control signal for reagent activity in a reagent control zone provides a signal at known reagent concentration (e.g. [R]=1). The control signal values can be plotted against reagent concentration to provide a curve or line. Where more than one reagent control is provided the data from the additional reagent control(s), having different reagent concentrations, can also be used to plot the curve or line. This can be compared against a standard curve or line to determine the extent of deterioration of substrate or reagent activity and to calculate any adjustment that is required to be made to the assay result. In an exemplary embodiment the control signal detected is an electrochemical signal (e.g. µA).
- Accordingly, in one exemplary embodiment, following formation of the liquid:air interface second liquid is forced from
buffer pouch 507 intosecond channel portion 4304 such that the second liquid is directed towardsjunction 4305. Prior to contact with the liquid:air interface, the secondliquid contacts electrodes junction 4305 to form the liquid sample:second liquid interface and second liquid flows intooverflow 524 to contact the reagent control zone where the reagent control signal is detected. The substrate control and/or reagent control signals are processed bymeter 400 to determine the activity of the substrate and/or reagent. The processing step can involve comparing the substrate control and/or reagent control signals against standard reference values for reagent and/or substrate activity, e.g. against an activity value for a laboratory standard. The determined control activity may be within a normal (expected) activity indicating that the assay may proceed and the assay result is valid. Alternatively the determined control activities may be outside tolerated ranges (e.g. activity too low) and the assay result may be indicated as 'Void'. In another exemplary alternative, by using the reagent control and substrate control values to determine the degree to which the activity of the substrate and/or reagent is diminished (or increased) a modification or correction may be applied to the assay result to provide a valid assay result that is displayed to the user. For example, the modification or correction assumes that the activity of all reagent and/or substrate contained in the assay device has deteriorated by the same amount or factor such that the assay result needs to be increased by a corresponding amount or factor. - In exemplary embodiments reagent activity is determined by detection of substrate activity, e.g. by detecting conversion of ABTS from reduced to oxidized form by the reagent. Thus, an on-board control for activity of substrate and reagent is provided by detecting the substrate activity (e.g. extent of oxidation of reduced ABTS substrate) at two positions in the second channel portion, each having different reagent concentrations. In one exemplary embodiment, one of the reagent concentrations can be zero. To ensure substrate activity is measured at zero reagent concentration it can be detected at the working electrodes prior to movement of magnetic particles across the junction.
- Although the assay device provides for a stable, substantially static liquid sample:second liquid interface small quantities of liquid sample can be washed into the second liquid and into
overflow 524. Reagent:magnetically susceptible particle complexes washed from the liquid sample into the second liquid will increase the quantity of reagent at the reagent control zone such that the reagent control signal detected is no longer a result only of interaction of the predetermined quantity of reagent deposited at the reagent control with the substrate but is affected by the presence of small quantities of additional reagent. - This problem can be overcome by partitioning the overflow channel into two parts. Referring to
Figures 12A and12B , the overflow channel is generally parallel to thefirst channel portion 4302 and is divided by a partition that is also substantially parallel to thefirst channel portion 4302 thereby forming afirst overflow channel 2301 and asecond overflow channel 2302. Thefirst overflow channel 2301 provides an excess channel volume to receive second liquid, displacing air throughvent 526 as the second liquid progresses along thefirst overflow channel 2301. This excess channel volume reduces the possibility of backflow of the second liquid. - The
second overflow channel 2302 is configured to receive at least some of the second liquid overflowing from the interface zone through an inlet. Distal to, and downstream of, the inlet thesecond overflow channel 2302 is tapered to form a narrow channel providing avent 2303 through which air is dispelled as liquid fills thesecond overflow channel 2302.Vent 2303 is connected to thefirst overflow channel 2301.Vent 2303 is sufficiently narrow and hydrophobic that second liquid is substantially completely prevented from flowing throughvent 2303 into thefirst overflow channel 2301. Accordingly, once filled thesecond overflow channel 2302 provides a defined volume of second liquid. - Particles washed away from the liquid sample:second liquid interface into the second liquid are carried in the second liquid close to the
wall 2305 separating thefirst channel portion 4302 andfirst overflow channel 2301 and into thefirst overflow channel 2301. Second liquid free or substantially completely free of reagent is thereby carried into thesecond overflow channel 2302. - The reagent control zone is positioned in the second channel portion in which detection of the reagent control signal takes place in a defined volume of second liquid. Any reagent particles washed into the overflow from the liquid sample:second liquid interface flow into the
first overflow channel 2301 and do not interfere with detection of reagent activity in the reagent control zone. Where the second liquid contains a predetermined known quantity of substrate, the defined volume of second liquid in thesecond overflow channel 2302 can be used to determine the extent of reaction of substrate and reagent and the activity of substrate and/or reagent. - According to the invention, a single overflow channel is provided. In this arrangement the reagent control zone is positioned sufficiently far away from the interface zone that any particles washed into the second liquid overflow settle out in the overflow channel prior to reaching the reagent control zone such that detection of the reagent control signal takes place in second liquid that is free or substantially completely free of reagent.
- Referring to
Figure 7 , theoverflow channel 524 has a length in the region of at least about 2 times the length of the second channel portion 4304 (e.g. at least about 2.5 times, at least about 3 times, at least about 4 times). The overflow channel defines a flow path initially substantially parallel to the flow path defined by the first channel portion, but thereafter may take any desired flow path to provide the required length of channel. In an exemplary embodiment the overflow channel may include one or more bend portions changing the direction of the flow path defined by the channel. - According to the invention the reagent control zone is located in the
overflow channel 524 at least about 20mm (e.g. at least about 30mm, at least about 40mm, at least about 50mm, at least about 60mm, at least about 70mm, at least about 80mm, at least about 90mm, at least about 100mm) downstream ofjunction 4305. In an exemplary embodiment the reagent control zone is located downstream of a first bend portion in the overflow channel (not including any bend portion at the connection between the second channel portion and theoverflow 524 immediately downstream of the junction 4305). - Referring to
Figure 2 ,meter 400 acceptstest assay device 500 and includesdisplay 406. Thedisplay 406 may be used to display images in various formats,.Display 406 can also be used to display information to patients.Display 406 can provide a user with an input region 404. Input region 404 can include keys. User instructions and queries are presented to the user ondisplay 406. The user can respond to the queries via the input region. -
Meter 400 also includes an assay device reader, which accepts diagnostictest assay devices 500 for reading. The assay device reader can measure the level of an analyte based on, for example, the magnitude of an optical change, an electrical change, or other detectable change that occurs on atest assay device 500. For reading assay devices that produce an electrical change in response to analyte, the assay device reader can include electrical systems for measuring the detectable change, including, for example, a voltameter or amperometer. - Referring to
Fig. 2 meter 400 is shown along withassay device 500.Meter 400 has aport 402 that receivesassay device 500. A user ofmeter 400 inserts anassay device 500 throughport 402 prior to performing an analysis of a sample. -
Meter 400 is configured to operateassay device 500 whenassay device 500 has been inserted throughport 402.Meter 400 includes a liquid reservoir actuator, a magnetic actuator, electrochemical detector, and a processor. Reservoir actuator is configured to actuatereservoir 507 ofdevice 500. The magnetic actuator is configured to manipulate (e.g., move and/or position) magnetically susceptible particles withinmicrofluidic network 508 ofassay device 500. The electrochemical detector is configured to determine the presence of analyte transported toelectrodes electrical contacts device 500 when received withinmeter 400. - In use,
assay device 500 is inserted intometer 400 viaport 402. A sample, e.g. a blood sample, is applied toinlet 510 ofassay device 500. An amount of the sample (e.g., at least about 5µl or 10 µl) moves into microfluidic network 508 (e.g. by capillary action). The sample interacts with reagents in the reagent zone. Target analyte is then transported to the detection zone where an electrochemical signal is recorded. Target analyte interacts withelectrodes interface 406. - In an exemplary embodiment, the analyte is N terminal pro-brain natriuretic peptide (NT-proBNP) and the sample material is whole blood from a human. The presence of NT-proBNP is indicative of a cardiac condition (i.e., a physiological condition related to the heart (e.g., a cardiac dysfunction such as heart failure)). Based at least in part on the result of the NT-proBNP determination, the presence of the cardiac condition can be determined. For example, it can be determined whether the human has experienced, is experiencing, or has a tendency to develop heart failure.
- Several reagents are present within the reagent zone of the assay device. The reagents include the following species; a first antibody capable of binding to NT-proBNP, a second antibody capable of binding to NT-proBNP concurrently with the first antibody, an anti-coagulant to prevent clotting of the blood sample within the reagent zone, at least one magnetic particle, an enzyme label that can be used to produce a detectable species, buffer salts, and at least one colloidal particle. The first antibody can be modified with biotin, the second antibody can be conjugated with the enzyme label. The second antibody-enzyme conjugate can be adsorbed onto a colloidal gold sol particle to increase the number of antibody-enzyme conjugates. The magnetic particle can be coated with streptavidin, which can be used to capture the biotin modified first antibody. When the reagents interact with NT-proBNP a conjugate complex is formed, which can be represented stylistically as follows:
- The streptavidin coated magnetic particle can accommodate a number of biotin modified antibodies. The biotin modified first antibody binds to a first unique region of NT-proBNP. The second antibody-enzyme conjugate binds to a second unique region of NT-proBNP. Second antibody-enzyme conjugate is provided pre-associated with gold sol particles thus increasing the number of enzyme labels that become part of the NT-proBNP antibody complex. In an exemplary embodiment a first monoclonal antibody, clone 15F11 was biotin modified, and a second antibody, clone 24E11 was conjugated with HRP.
- The following are non-limiting examples.
- A human blood sample is added to the
assay device 500 atinlet 510. The blood contains an amount of an analyte: N-terminal truncated pro-brain natriuretic peptide (NT-proBNP). - The sample of blood enters the
first channel portion 4302, e.g. via capillary action, where it mixes with reagents in the reagent zone. The reagents in the reagent zone include streptavidin coated magnetically susceptible particles and biotinylated first binding agent which is an anti-NT-proBNP antibody 15C4 (HyTest Ltd.; Catalogue #:4NT) and horseradish peroxidase ("HRP") conjugated to a second binding agent which is anti-NT-proBNP antibody 15F11 or 29D12 (HyTest Ltd.; Catalogue #:4NT) (the antibody-linked enzyme). The assay device and included reagents are provided in a dry state. Addition of a liquid sample to the assay device (i.e., to the inlet and first channel portion) re-suspends dry reagents. - The reagents are re-suspended in solution with the blood, and form a mixture. The streptavidin coated magnetically susceptible particles bind to the biotinylated first binding agent to form a conjugate (the antibody-linked magnetically susceptible particle). The NT-proBNP in the blood is also bound by the first binding agent and a ternary complex of NT-proBNP bound antibody-linked magnetically susceptible particle is formed. A magnetic field is applied such that the magnetically susceptible particles undergo an induced motion (e.g., a periodic or oscillatory motion) to promote resuspension and mixing of the reagents with the sample.
- The blood sample fills the
first channel portion 4302 and on reachingjunction 4305, the liquid forms a meniscus. The change in cross-sectional area of the channel atjunction 4305 does not allow the blood sample to fill thesecond channel portion 4304. Rather, capillary pressure in the second channel portion exceeds any capillary forces that draw the sample liquid beyondjunction 4305 into thesecond channel portion 4304.Junction 4305 thus acts as a capillary stop, preventing substantial liquid sample flow beyond that point. At this stage, a blood sample:air interface is formed by the blood meniscus atjunction 4305. - After mixing of the reagents and blood sample, a magnetic field is applied to the
first channel portion 4302. The applied field is manipulated so as to move the magnetically susceptible particles, and all components bound to them. The magnetically susceptible particles are magnetically moved along thefirst channel portion 4302 towardjunction 4305. - A buffer liquid is added to the device at the
second inlet 520. Abuffer pouch 507 incorporated into the device delivers the reaction buffer. The buffer liquid contains 10mM of theredox mediator 2,2'-azino-bis-(3-ethylbenzo-thiazoline-sulfonic acid) (ABTS), 10mM H2O2, 150mM KCl, 125mM sodium acetate; 0.1% v/v Tween20, made to a final pH 4.2. The buffer does not contain analyte (NT-proBNP). The buffer liquid flows along thesecond channel portion 4304 tojunction 4305, where the buffer liquid contacts the blood sample at the blood:air interface to form a blood:buffer interface. - The magnetically susceptible particles (and all that is bound to them) are moved across the blood:buffer interface by moving the applied magnetic field across the
junction 4305 into thesecond channel portion 4304 and towards the workingelectrode 516w. The formation of the blood:buffer interface facilitates the magnetic movement of the magnetically susceptible particles (and all that is bound to them) from the blood to the buffer, leaving interfering sample components and analytes that are not of interest in the blood in thefirst channel portion 4302. The magnetically susceptible particles and all that is bound to them, including the NT-proBNP (in the form of a ternary complex of NT-proBNP with antibody-linked magnetically susceptible particle and antibody-linked enzyme) are transferred to the second liquid in thesecond channel portion 4304. - The magnetically susceptible particles bound to NT-proBNP are next moved to the working
electrode 516w by manipulation of the applied magnetic field. The magnetically susceptible particles are magnetically positioned and held at the detection zone for an incubation time of e.g. 1 minute. Magnetically susceptible particles bound to NT-proBNP and the second binding agent:HRP conjugates are detected electrochemically by HRP mediated catalysis of hydrogen peroxide and ABTS to water and oxidised-ABTS. At the end of the incubation time the electrochemical current produced by the reduction of oxidized ABTS at the electrodes is measured at the working electrode for a measurement period (e.g. 3 seconds). - The detected electrochemical current is received in
meter 400 and compared against a corresponding calibration dataset to determine an amount and/or concentration of NT-proBNP. The meter displays or communicates an assay result to the user. - Electrochemical measurements can be made using a single time point of HRP turnover time. A typical dose response curve for concentrations of 0-20,000 pg/ml NT-proBNP in the liquid sample is shown in
Figure 17 . The performance of the electrochemical NT-proBNP assay may be optimised by extending the measurable range and linearising the response at the higher NT-proBNP concentrations. To achieve this we identified whether the plateau effect was a reagent, electrochemical or combined reagent and electrochemical limitation. - Within the current electrochemical measurement of NT-proBNP, effectively we are measuring the concentration of HRP; this is illustrated in
Figure 18 . Therefore dose response curves of NT-proBNP are effectively current vs. HRP concentration. - The ability to measure the HRP concentration electrochemically via the mediator ABTS provides the flexibility to tune the immunoassay response. Typically, once the particles were moved out of the blood and dragged to the electrode, captured HRP was allowed to react for a 1 minute turnover period (incubation time). No potential was applied to the electrode until after the 1 minute HRP turnover period, the subsequent potential applied was used to reduce the oxidised ABTS generated by the HRP.
- To investigate the limitation of a 1 minute HRP turnover period, HRP titrations were performed to investigate the HRP turnover time on the sensitivity, linearity and range of the response. In these experiments the HRP was homogeneously distributed within the channel and not concentrated in the vicinity of the electrode when placed on the electrode via the magnetic particles.
- The linear range of the HRP is seen to vary with turnover time. A 10 minute turnover time results in an approximately linear range up to 5000 pM HRP; a 1 minute turnover time results in an approximately linear range up to 20,000 pM HRP; a 30 second turnover time results in a approximately linear range of 50,000 pM HRP; a 15 second turnover time results in an approximately linear range of 80,000 pM HRP.
- The effect of HRP turnover time is summarised in
Figure 18 . There is a trade off between increased linearity of the HRP response and sensitivity, as the HRP range (pM) is increased the HRP measurement becomes less sensitive e.g. 10 minutes - limit of detection (LOD) at least 25 pM; 1 min - LOD 50-100 pM; 30secs 100 pM; 15 seesLOD 100 pM. - From the titration data we conclude that we can significantly increase the measurable HRP concentration (pM) range and the linear component.
- Experiments were performed to test this hypothesis, the summary results are shown in
Figure 19 . - The application of reduced HRP turnover times has a significant effect upon extending and linearising the NT-proBNP response. This represents a significant optimisation for the electrochemical measurement of NT-proBNP.
- It is desirable to be able to measure NT-proBNP concentrations over a 50-20,000 pg/ml range. This is a dynamic range for an immunoassay to measure. It would also be desirable to distinguish a doubling in NT-proBNP concentration. It would also be desirable to linearise the electrochemical response over the higher NT-proBNP concentrations.
- For example, a 15 second turnover time allows the measurement of up 40,000 pg/ml NT-proBNP and easily allows the ability to measure the doubling of 5000 to 10000 to 20000 to 40000 pg/ml. This result demonstrates how the assay can be tuned for optimum performance.
- For example if the 15 sec measurement is plotted on a semi log curve a good linear response is observed as shown in
Figure 20 (x-axis shows NT-proBNP concentration). - This result provides a good model system to understand the complex interplay between many parameters. A two point electrochemical measurement can be made to measure the desired range with optimum performance, for example a 15 second measurement to capture the high NT-proBNP concentrations as shown and then a second measurement (e.g. 1, 2, 3 minutes) to measure the low NT-proBNP concentrations resulting in 2 calibrations curves for maximum sensitivity and performance.
- Further HRP titration experiments were performed to investigate the relationship between increased HRP turnover time and increased HRP LOD. A clear trend was observed. The LOD and the associated slope of the response changes as a function of HRP turnover time. Specifically LOD of 10 pM are observed for the 10, 7 and 5 min HRP turnover time whilst 25 pM is observed for 3 mins and a 100 pM LOD for a 1 minute HRP turnover time. Significant increases in performance could be observed using a prolonged HRP time period for measurement of lower NT-proBNP concentrations compared with the previously used 1 minute turnover time. For example a secondary time point measurement after 5 minutes HRP turnover would result in changing the HRP LOD from 100 pM to 10 pM (x10 difference).
- Two point HRP titrations experiments were performed. Identical titration responses were observed whether a single HRP concentration is measured in a single or dual time point manner, depletion of the generated oxidised ABTS over a 3 second period does not affect the signal obtained with the second time point measurement (300 sec). Shorter measurement times of the oxidised ABTS (<300 secs) may allow multiple time points to be measured.
- Other embodiments are conceivable as long as they fall within the scope of the following claims.
Claims (7)
- A microfluidic assay device (500) comprising:an inlet (510) in fluid connection with a first portion (4320) of a channel, the inlet (510) configured to receive a liquid;a second portion (4304) of the channel connected to the first portion (4320) at a junction (4305); andmagnetically susceptible particles disposed in the first portion (4320) of the channel, characterized in thatthe first portion (4320) of the channel has a main channel height h1 and a channel height h'1 at the junction (4305), wherein h1>h'1 and wherein at the junction (4305), the first portion (4320) of the channel has height h'1 and the second portion (4304) of the channel has height h2, wherein h2>h1>h'1 and the ratio h'1:h2 is at least 1:2wherein the device (500) is configured to form, with a liquid received by the inlet, a liquid interface proximal the junction (4305), the device further (500) characterized by:a reservoir (507) containing a quantity of second liquid and configured to deliver second liquid released from the reservoir into the second portion (4304) of the channel such that the second liquid flows towards the junction (4305),a single overflow channel (524) comprising a reagent control zone having one or more detection electrodes (3601) to detect the reagent control signal which reagent control zone is located in the overflow channel (524) at least about 20 mm downstream of the junction (4305) such that detection of the reagent control signal can take place in the second liquid that is free or substantially completely free of reagent, andat least one sensor configured on the second channel portion to detect a signal from the second liquid.
- The microfluidic assay device (500) according to claim 1 wherein proximal to the junction (4305) one or more of the internal wall(s) of the first channel portion are hydrophobic or
wherein proximal to the junction (4305) one or more of the internal wall(s) of the first portion (4320) of the channel have a hydrophobic patch, a hydrophobic line or a hydrophobic ring extending around the circumference of the first channel portion. - The microfluidic assay device (500) according to claim 1 or 2 wherein the inlet is partitioned into one or more first compartments in fluid connection with the first channel portion thereby defining a total volume of the first channel portion and first compartments (V1), and one or more second compartments not in fluid connection with the first channel portion; and
wherein said overflow channel portion partitioned into a first overflow channel portion proximal the junction (4305) and a second overflow channel portion distal to the junction (4305), wherein the reagent control zone is located in the second overflow channel portion. - The microfluidic assay device (500) according to claim 3 wherein the main longitudinal axis of at least one of the first and second overflow portions is substantially parallel to the first channel portion.
- The microfluidic assay device (500) according to claim 1, wherein said overflow channel portion is partitioned into a first overflow channel portion proximal the junction (4305) and a second overflow channel portion distal to the junction (4305), wherein the reagent control zone is located in the second overflow channel portion.
- The microfluidic assay device (500) according to claim 1 further including a substrate control to determine the activity of the substrate at any chosen location in the second channel portion (4304) provided that location is substantially free of reagent.
- The microfluidic assay device (500) according to claim 6 wherein a substrate control signal is determined at electrodes (516w, 516r, 516c) and is detected in the second liquid upstream of junction (4305) and prior to transfer of magnetically susceptible particles across the junction (4305) into the second liquid.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2007/003738 WO2009044088A1 (en) | 2007-10-02 | 2007-10-02 | Assay device and method |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2205357A1 EP2205357A1 (en) | 2010-07-14 |
EP2205357B1 true EP2205357B1 (en) | 2020-07-15 |
Family
ID=39431219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07823995.1A Active EP2205357B1 (en) | 2007-10-02 | 2007-10-02 | Assay device and method |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2205357B1 (en) |
CN (1) | CN202122963U (en) |
WO (1) | WO2009044088A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022087544A1 (en) * | 2020-10-23 | 2022-04-28 | Essenlix Corporation | Barrier selector assay |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6606700B1 (en) | 2000-02-26 | 2003-08-12 | Qualcomm, Incorporated | DSP with dual-mac processor and dual-mac coprocessor |
GB0910291D0 (en) * | 2009-06-16 | 2009-07-29 | Biochip Devises Pte Ltd | Method for conducting multiple reactions in a single reaction tube |
CN102687018B (en) * | 2009-11-16 | 2015-07-15 | 硅生物装置有限公司 | Filtration device for assays |
ATE542136T1 (en) | 2010-03-15 | 2012-02-15 | Boehringer Ingelheim Int | APPARATUS AND METHOD FOR MANIPULATION OR EXAMINATION OF A LIQUID SAMPLE |
EP2593230A2 (en) * | 2010-07-16 | 2013-05-22 | Vanderbilt University | Low resource processor using surface tension valves for extracting, concentrating and detecting molecular species |
AU2013204332B2 (en) | 2012-04-16 | 2015-07-16 | Commonwealth Scientific And Industrial Research Organisation | Methods and systems for detecting an analyte or classifying a sample |
US9869675B2 (en) | 2013-03-13 | 2018-01-16 | Vanderbilt University | Low resource processor using surface tension valves for extracting, concentrating, and detecting whole cells |
CN104569376B (en) * | 2013-10-09 | 2017-11-10 | 常州博闻迪医药科技有限公司 | A kind of chromatography detection technique device of magnetic particle mediation and application thereof |
CN103575882B (en) * | 2013-11-15 | 2015-11-25 | 苏州华迈兴微医疗科技有限公司 | The labelling immunoassay method of whole blood and instant detection system |
IL242807A0 (en) | 2015-11-26 | 2016-04-21 | Novamed Ltd | Assay device |
JP7062954B2 (en) * | 2016-02-10 | 2022-05-09 | ソニーグループ株式会社 | Blood coagulation analyzer and blood coagulation analysis method |
JP2020510406A (en) | 2016-11-14 | 2020-04-09 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション | Protease sensor molecule |
JP7246372B2 (en) | 2017-08-08 | 2023-03-27 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション | carb sensor |
JP7462043B2 (en) * | 2019-11-22 | 2024-04-04 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド | Apparatus, system and method for transferring liquids containing aggregates - Patents.com |
CN112827517B (en) * | 2019-11-25 | 2023-05-02 | 杭州微著生物科技有限公司 | Use method and device of micro-fluidic chip |
CN114544854A (en) * | 2022-02-08 | 2022-05-27 | 北京普立泰科仪器有限公司 | Detection device and detection method for cyanide in aqueous solution |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4935147A (en) * | 1985-12-20 | 1990-06-19 | Syntex (U.S.A.) Inc. | Particle separation method |
US5279936A (en) * | 1989-12-22 | 1994-01-18 | Syntex (U.S.A.) Inc. | Method of separation employing magnetic particles and second medium |
WO2002037091A1 (en) * | 2000-10-31 | 2002-05-10 | Caliper Technologies Corp. | Microfluidic methods, devices and systems for in situ material concentration |
WO2007002579A2 (en) * | 2005-06-23 | 2007-01-04 | Bioveris Corporation | Assay cartridges and methods for point of care instruments |
ITTO20060226A1 (en) * | 2006-03-27 | 2007-09-28 | Silicon Biosystem S P A | METHOD AND APPARATUS FOR PROCESSING AND OR ANALYSIS AND OR SELECTION OF PARTICLES, IN PARTICULAR BIOLOGICAL PARTICLES |
GB2436616A (en) * | 2006-03-29 | 2007-10-03 | Inverness Medical Switzerland | Assay device and method |
-
2007
- 2007-10-02 CN CN2007901000110U patent/CN202122963U/en not_active Expired - Lifetime
- 2007-10-02 EP EP07823995.1A patent/EP2205357B1/en active Active
- 2007-10-02 WO PCT/GB2007/003738 patent/WO2009044088A1/en active Application Filing
Non-Patent Citations (1)
Title |
---|
None * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022087544A1 (en) * | 2020-10-23 | 2022-04-28 | Essenlix Corporation | Barrier selector assay |
Also Published As
Publication number | Publication date |
---|---|
WO2009044088A1 (en) | 2009-04-09 |
EP2205357A1 (en) | 2010-07-14 |
CN202122963U (en) | 2012-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2205357B1 (en) | Assay device and method | |
US9063132B2 (en) | Assay device and method | |
US10509032B2 (en) | Assay device and method | |
US9863942B2 (en) | Biosensor apparatus and methods of use | |
US20190072544A1 (en) | Sample metering device and assay device with integrated sample dilution | |
US9846152B2 (en) | Assay devices with integrated sample dilution and dilution verification and methods of using same | |
AU2008279042B2 (en) | Electrochemical analyte detection apparatus and method | |
US10058867B2 (en) | Sample metering device and assay device with integrated sample dilution | |
US20100015728A1 (en) | Assay Device and Method | |
US20120142025A1 (en) | Ratiometric Immunoassay Method and Blood Testing Device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100331 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1141753 Country of ref document: HK |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20161011 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200130 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ABBOTT RAPID DIAGNOSTICS INTERNATIONAL UNLIMITED COMPANY |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602007060459 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1290379 Country of ref document: AT Kind code of ref document: T Effective date: 20200815 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1290379 Country of ref document: AT Kind code of ref document: T Effective date: 20200715 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201016 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201015 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201116 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201115 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602007060459 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
26N | No opposition filed |
Effective date: 20210416 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201002 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20201031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201031 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201031 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201002 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200715 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230623 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230919 Year of fee payment: 17 Ref country code: GB Payment date: 20230914 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230914 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20230915 Year of fee payment: 17 |